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ABSTRACT
Tenofovir (TFV) is a reverse transcriptase inhibitor that is approved by the United States Food
and Drug Administration (FDA) to treat HIV and chronic Hepatitis B. It has a long half-life,
allowing for once a day dosing and is effective in treatment of both naive and experienced
patients. It is administered orally as tenofovir disoproxil fumarate (TDF) and is deesterified in
plasma to the active drug TFV. However, renal impairment is associated with its use; TFV can
induce decreased glomerular filtration rate (GFR) and free calcitriol, renal failure, and Fanconi
Syndrome. The exact mechanism of toxicity currently remains unknown, largely due to limited
experimental models. The purpose of this study was to investigate the mechanisms of
cytotoxicity and oxidative damage observed in HK-2 cells following treatment with TFV and to
determine if managing oxidative damage mitigates toxicity. TFV is the active form of TDF and
was used for all studies. HK-2 cells were grown to confluency for 48 h and then exposed to 028.8 µM TFV for 24, 48, or 72 h. The vehicle used for all studies was phosphate buffered saline
(PBS). TFV induces a loss of cell viability compared to the control within 24 h as shown by an
MTT assay, Trypan Blue Exclusion cell counts, and lactate dehydrogenase (LDH) leakage.
Oxidative stress and mitochondrial damage were assessed in whole cell lysate and different cell
fractions using OxyBlot and western blot for 4-hydroxynonenol (4-HNE), tumor necrosis factor
alpha (TNFα), caspase 3, 8, and 9, MnSOD, ATP Synthase, and cytochrome c and showed an
increase in protein carbonylation and loss of mitochondrial membrane integrity following 72 h
exposure to 28.8 µM TFV. TFV induces apoptosis at 72 h exposure as shown by western blot
analysis of cytochrome c leakage and activation of caspase 3 and 9. Studies conducted using
Seahorse XFp technology determined that TFV alters mitochondrial function. Studies were
conducted using a 1 h pretreatment with antioxidants resveratrol, N-acetyl-L-cysteine, or

xiii

ascorbic acid, and results showed protection of cell viability following 24 h exposure to 3 and
14.5 μM TFV. These studies suggest that mitochondrial damage and oxidative stress occur in
HK-2 cells treated with TFV and that controlling oxidative damage may help prevent toxicity
from developing. Additional knowledge of subcellular events associated with tenofovir
nephrotoxicity can be used to develop clinical methods to mitigate toxicity.
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Abstract
Over one million people in the United States are living with Human Immunodeficiency
Virus (HIV) which may progress to Acquired Immunodeficiency Syndrome (AIDS). The use of
antiviral therapy has successfully controlled the rate of viral growth in patients. Antiviral agents
improve the quality of life and reduce the potential for spreading HIV; HIV is currently
considered a chronic disease provided patients are compliant with their antiviral medications.
Tenofovir is a nucleoside transcriptase inhibitor that prevents viral replication and is approved
for treatment of HIV and chronic hepatitis B infection. Tenofovir is an antiretroviral drug used
alone and in combination with other nucleoside reverse transcriptase inhibitor agents to lower
viral load in HIV patients. Tenofovir is administered as a prodrug in order to increase
bioavailability. The prodrug forms of tenofovir are tenofovir disoproxil fumarate approved in
2001 and tenofovir alafenamide approved in 2016. Tenofovir is extensively used in controlling
HIV as it is administered once daily allowing for good compliance. This minireview discusses
the changes in dosing that are needed in the presence of renal impairment which is a common
occurrence with HIV chronic disease progression. The impact of food, age, and drug transporters
on tenofovir absorption and clearance will be discussed. The potential special conditions
occurring with fixed combination doses containing tenofovir will also be reviewed, including the
use of cobicistat, a cytochrome P450 inhibitor. The short review also addresses some newer
preparations using niosomes to improve tenofovir absorption and delivery to the target cells.
Introduction
Human Immunodeficiency Virus (HIV) is a virus that decimates the immune system.
HIV targets a specific type of white blood cells known as T-cells, T-lymphocytes or CD4 cells.
A decline in CD4 cell count mediated by HIV leaves the body open to opportunistic infections.
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At one time, HIV rapidly progressed to Acquired Immunodeficiency Syndrome (AIDS) and
death, but advancements in highly active antiretroviral therapy (HAART) have made HIV a
chronic condition rather than a death sentence. Tenofovir (TFV), formerly known as PMPA [9(R)-(2-phosphonomethoxypropyl) adenine] is a reverse transcriptase inhibitor that has potent and
selective inhibition of HIV and herpes viruses’ reverse transcriptase. TFV is an acyclic
nucleotide analogue of adenosine 5’ monophosphate that is phosphorylated intracellularly by
adenylate kinase to its active form, tenofovir diphosphate. TFV is effective in cases of
nucleoside resistant HIV infection, making it a first line agent for treatment of this disease
(Miller, Margot, Hertogs, Larder, & Miller, 2001; Squires et al., 2003).
Despite its efficacy, poor bioavailability was a limiting factor in development of TFV as
a clinical agent. Oral administration of TFV had 18% bioavailability in beagles and 5.3% in
monkeys (Cundy et al., 1998; Shaw et al., 1997). Research efforts subsequently focused to
improve bioavailability by altering TFV formulation but maintaining antiviral activity. Two
methyl carbonate esters were added to form the prodrug tenofovir disoproxil fumarate (TDF),
which demonstrated equivalent antiviral activity with bioavailability increased to 30.1% in
beagles and 25% in humans (Barditch-Crovo et al., 2001; Shaw et al., 1997). TDF was approved
in Fall 2001 by the United States Food and Drug Administration (FDA) to treat chronic Hepatitis
B and HIV in conjunction with other agents (Gilead Sciences, 2001). There are several factors
that alter TDF bioavailability and pharmacokinetics, including age, sex, and food intake. This
article provides a review of tenofovir bioavailability as well as factors that have an impact on
TFV pharmacokinetics in human and animal models.
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Pharmacokinetics and Bioavailability of Tenofovir Disoproxil Fumarate
TDF is formulated into a tablet for oral administration with a standard dose of 300 mg.
TDF has a higher lipophilicity than TFV. The LogP, a measure of the partition coefficient
between octanol and water, is 2.1 for TDF compared to -1.6 for TFV. The higher partition
coefficient would enable increased intestinal drug absorption. As a result of higher lipophilicity,
TDF has an oral bioavailability of 25% in HIV-1 infected patients (Barditch-Crovo et al., 2001).
Following absorption, TDF is cleaved in the plasma by esterases (Figure 2) first to a monoester
intermediate, and then to TFV (Choi, Bui, & Ho, 2008; Shaw et al., 1997). This hydrolysis is
effective enough that TDF is not observed in systemic plasma samples.

Figure 1. Structure of deoxyadenosine 5’ triphosphate (A) and tenofovir diphosphate (B)
After intestinal absorption and plasma hydrolysis, TFV is phosphorylated intracellularly
by adenylate kinase to its active form, tenofovir diphosphate (TDP) (Figure 3). As a nucleotide
analogue, TFV diphosphate competes with deoxyadenosine 5’ triphosphate (Figure 1) for
incorporation into the growing DNA strand during HIV transcription and blocks the activity of
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reverse transcriptase, leading to elongation termination (Balzarini et al., 1993; Robbins, Srinivas,
Kim, Bischofberger, & Fridland, 1998).

Figure 2. Conversion of tenofovir disoproxil fumarate to tenofovir by intestinal and plasma
esterases.

Intravenous administration of 1 mg/kg TDF has a steady state volume of distribution of
813 mL/kg, indicating that tissue distribution is extensive and exceeds total body water. Cmax of
the same intravenous dose is approximately 2.7 μg/ml, and TFV serum concentration decreases
in a biphasic manner (Deeks et al., 1998). The measured area under the curve (AUC) was 3.024
μg ∙h/mL. The oral bioavailability of TDF was calculated by comparing the AUC for a 300 mg
oral dose to the AUC for a 1 mg/kg intravenous dose; oral TDF has 25% bioavailability when
compared to an intravenous dose (Barditch-Crovo et al., 2001).

Figure 3. Intracellular activation of tenofovir to tenofovir diphosphate by adenylate kinase
5

The half-life for a single intravenous TDF injection was 7 h compared to 12 h for a single
oral dose of 300 mg TDF (Barditch-Crovo et al., 2001; Deeks et al., 1998; Hawkins et al., 2005).
The intracellular half-life of TDF is estimated to be 12-50 h (Robbins et al., 1998).
The pharmacologic antiviral activity of TDF and ultimately TFV is proportional to the
intracellular concentration in target cells. A single oral dose of TDF to macaques provided
almost 8 fold higher intracellular levels of the active TFV-diphosphate compared to a single subcutaneous injection of TFV (Durand-Gasselin et al., 2009). Additionally, oral TDF shows greater
accumulation in peripheral blood mononuclear cells (PBMCs) when given as an oral prodrug
rather than a subcutaneous injection of TFV to macaques (Durand-Gasselin et al., 2009). The
bioavailability in macaques was 31%, which was similar to humans (Barditch-Crovo et al.,
2001). These findings suggest that TDF first enhanced bioavailability, but also provided
improved delivery to the target cells. The excellent uptake into cells allows for once daily
dosing. Once daily dosing increases compliance, which will promote therapeutic success, which
is important in controlling HIV as a chronic disease.
In general, differences in TDF pharmacokinetics are not apparent when comparing oral
and intravenous routes of administration. Oral TDF has equivalent pharmacokinetics to
intravenous TDF. Once Cmax is reached, serum TFV concentrations decline in a biphasic
manner. TFV is excreted 92% unchanged by the kidney and 4.5% unchanged in feces. Renal
TFV clearance exceeds calculated creatinine clearances, indicating that TFV is actively secreted
by the kidneys (Barditch-Crovo et al., 2001; Cundy et al., 1998; Durand-Gasselin et al., 2009).
In vitro transport studies indicate that TFV is a substrate for the multidrug resistance-associated
protein 4 (MRP4), an apical membrane efflux transporter (A. S. Ray et al., 2006). TFV was not a
substrate for MRP2. These in vitro studies would suggest that active tubular secretion of TFV

6

into the nephron lumen is mediated by MRP4. It is worth noting that while TFV is not a
substrate of MRP1, MRP2, or MRP 3, at concentrations exceeding 50 μM, TFV does inhibit
these transporters in Madin-Darby canine kidney II (MDCKII) cells (Weiss, Theile, KetabiKiyanvash, Lindenmaier, & Haefeli, 2007).
Pharmacokinetics and Bioavailability of TDF in Patients with Renal Insufficiency
TDF pharmacokinetics and bioavailability differ in patients with renal insufficiency,
which is an important consideration in individuals with HIV. The frequency of acute kidney
injury is more common in HIV infected individuals and can progress to end stage renal disease.
In 2005, it was estimated that in the United States, almost 3,000 people had end stage renal
disease related to HIV. A decline in renal function is a frequent occurrence in HIV disease
progression (Schwartz & Klotman, 1998; Wyatt et al., 2009). HIV-associated nephropathy
(HIVAN) primarily affects the glomerulus, and is characterized by proteinuria, elevated serum
creatinine and blood urea nitrogen (BUN), focal segmental glomerulosclerosis (FSGS), and
microcystic tubular dilation. Renal lesions lead to the collapse of the glomeruli and rapid
progression to kidney failure (Laurinavicius, Hurwitz, & Rennke, 1999; P. E. Ray, 2012).
While HIVAN occurs less frequently in patients whose HIV is well controlled with
antiretroviral therapy (ART) (Fabian, Naicker, Goetsch, & Venter, 2013), renal insufficiency
should be considered when using TDF. In a study conducted in patients with varying degrees of
renal insufficiency, patients with moderate and severe renal impairment (noted as creatinine
clearance (CLCR) of 30-49ml/min and <30ml/min, respectively) had an AUC 2-6 fold higher than
in patients with normal renal function. The increase in AUC was most likely due to a decrease in
TFV clearance that was directly proportional to the observed decreases in CLCR (Kearney,
Flaherty, & Shah, 2004).
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Patients treated with TDF do have an increased incidence of renal impairment, and there
is a positive correlation between increased TFV serum concentrations, duration of treatment with
TDF, and incidence of renal toxicity (Ezinga, Wetzels, Bosch, van der Ven, and Burger, 2014;
Fux et al., 2007; Quesada et al., 2015; Verhelst et al., 2002). TDF is associated with increased
serum creatinine and plasma vitamin D binding, decreased free calcitriol levels and glomerular
filtration rate (GFR), renal failure, and Fanconi Syndrome (Del Palacio, Romero, & Casado,
2012; Hall, Hendry, Nitsch, & Connolly, 2011; Havens et al., 2013). Fanconi syndrome is a
disorder of renal tubular function characterized by excess renal excretion of potassium,
phosphate salts, protein, urate, and glucose. Clinical studies indicate that the mitochondria of the
proximal tubules are the target of TFV induced toxicity as shown by enlarged and malformed
mitochondria in electron microscopy cross sections (Cote et al., 2006; Hall et al., 2011; Herlitz et
al., 2010; Woodward et al., 2009). Proximal tubular mitochondrial toxicity has also been
described in mice and rats treated with TFV as shown by disruptions in mitochondrial cristae and
a reduction in mitochondrial DNA (mtDNA) levels (Kohler et al., 2009; Lebrecht et al., 2009).
Changes in TDF administration are recommended for patients with decreased renal
function to reduce plasma concentrations and to prevent worsening of renal damage. In patients
with moderate impairment (CLCR 30-49ml/min), 300 mg dose of TDF should be reduced in
frequency to once every 48 h instead of once daily. In patients with severe impairment (CLCR
10-29ml/min) or those who are on hemodialysis, the 300 mg dose should be administered every
72-96 h or once every 7 days, respectively (Gilead Sciences, 2001).
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Pharmacokinetics and Bioavailability of TDF in Fixed Dose Combination Tablets
To simplify HIV treatment regimens and increase compliance, TDF is commonly paired
with other antiretrovirals in single dose combination tablets. The drugs currently combined with
TDF in fixed dose combinations are: emtricitabine (FTC, 200 mg), efavirenz (EFV, 600 mg),
rilpivirine (RPV, 25 mg), the integrase strand transfers inhibitor elvitegravir (EVG, 150 mg) and
the CYP 3A4 inhibitor cobicistat (COBI, 150 mg). The most common formulations are:
TDF/FTC, TDF/FTC/EFV, TDF/FTC/RPV and TDF/FTC/EVG/COBI. Each formulation
includes TDF as a standard 300 mg dose. Bioequivalence is evaluated in combination tablet
formulations by maintenance of pharmacokinetic parameters Cmax, AUC, and t1/2 within a
confidence interval (CI) of 80-125% of the reference formulation.
The first fixed dose combination approved by the FDA for treatment of HIV contained
TDF/FTC/EFV. FTC, EFV and TDF all have half-lives that are suitable for once a day dosing
(FTC, 39h; EFV, 23 h; TDF, 15-60 h) (Barditch-Crovo et al., 2001; DiCenzo et al., 2003;
Hawkins et al., 2005; Saag, 2006). When studied as a fixed-dose combination tablet, all
pharmacokinetic parameters had geometric mean ratios close to 100% and 90% CI within the
bioequivalence bounds of individual formulations, indicating that TDF, EFV, and FTC can be
combined into a once daily combination tablet (Mathias et al., 2007). The combination of
TDF/FTC/EFV is FDA approved as a complete regimen for HIV treatment and can also be used
in combination with other HIV medications (Gilead Sciences, 2006).
TDF/FTC/RPV combination provides two nucleos(t)ide reverse transcriptase inhibitors
(TDF/FTC) with a non-nucleoside reverse transcriptase inhibitor, RPV to treat HIV. Initial
studies showed that addition of 25mg RPV to a TDF/FTC treatment regimen showed
equivalence in HIV suppression when compared to TDF/FTC + EFV regimens and had less
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adverse effects than EFV (Cohen et al., 2011; Molina et al., 2011). RPV has a t1/2 of
approximately 50 h, making it a suitable candidate for inclusion in a once daily combination
tablet (Cohen et al., 2013). In a bioequivalence study, all pharmacokinetic parameters of a
TDF/FTC/RPV single dose tablet demonstrated a 90% CI within the bioequivalence bounds of
individual formulations, indicating that TDF, FTC, and RPV can be combined into a once daily
combination tablet. While both TDF and FTC are approved to be taken with or without a meal,
RPV bioavailability is reduced 40% in a fasted state alone and in a combination tablet.
Therefore, TDF/FTC/RPV should be taken with food (Mathias et al., 2012).
TDF/FTC combination tablets also demonstrate bioequivalence for all tested
pharmacokinetic parameters when compared to individual therapy (Blum, Chittick, Begley, &
Zong, 2007). TDF/FTC is FDA approved to treat HIV-1 in conjunction with other therapies, but
is not considered a complete regimen. TDF/FTC is also FDA-approved for use in pre-exposure
prophylaxis (PrEP) therapy to prevent the transmission of HIV-1 between sexual partners
(Anderson et al., 2012; Baeten et al., 2012; Grant et al., 2010). The use of TFV-containing
regimens for PrEP is discussed in further detail in the “Tenofovir as a Prophylactic Agent”
section below.
Recently COBI has been included in HAART to treat HIV. While it has no antiviral
activity on its own, COBI is a pharmacoenhancer for drugs that are metabolized by cytochrome
P450 3A enzymes (CYP3A). COBI is a potent CYP3A inhibitor, and is commonly used with
protease and integrase inhibitors such as EVG in the treatment of HIV. In a fixed dose
combination study, administration of COBI/TDF/EVG combination tablets showed
bioequivalence; however, TDF Cmax was increased 30% but AUC was largely unaffected
(German, Warren, West, Hui, & Kearney, 2010). COBI may alter the half-life of other drugs
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taken concurrently that are biotransformed by CYP3A as inhibition by COBI may slow
biotransformation by CYP3A. COBI is a substrate for CYP3A and treatment with agents that
induce or inhibit CYP3A has the potential to alter the effects of COBI (Sherman, Worley, Unger,
Gauthier, & Schafer, 2015).
This increase in Cmax may be due to COBI’s transient inhibition of P-glycoprotein efflux
transporter (Pgp); TFV is a recognized substrate of the Pgp transporter (German et al., 2010;
Lepist et al., 2012). It is worth noting that COBI inhibition of P-glycoprotein is weak, much like
other protease inhibitors such as ritonavir (RTV); COBI, RTV, and other protease inhibitors do
not inhibit efflux transporters at pharmacologically relevant concentrations in systemic
circulation (Cihlar et al., 2007; Polli et al., 1999; Ray et al., 2006; van der Sandt et al., 2001;
Washington, Duran, Man, Sikic, & Blaschke, 1998) but may reach concentrations high enough to
inhibit efflux transporters in the gut (Ray et al., 2006; Tong et al., 2007).
Effect of Food Intake on TDF Bioavailability
Taking TDF with food has shown to improve bioavailability. However, it does not
appear that the type of meal matters, as no changes in pharmacokinetic parameters are seen with
administration of a standard meal, high fat meal, or protein-rich meal. In a study of healthy
Japanese males, participants ingested a standard meal (11.4g protein, 9.6g fat, and 72.2g
carbohydrates) or a protein-rich drink (8.8g protein, 8.8g fat, 34.3g carbohydrates) prior to
administration of a 300 mg dose of TDF. There was a 28% decrease in both AUC and Cmax when
TDF was administered in a fasted state compared to administration following a standard meal or
a protein-rich drink. Although Cmax was slightly lower in the protein-drink group (554 ng/ml vs.
613 ng/ml), AUC and t1/2 were not different between meals, indicating that a standard meal and a
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protein-rich drink produce bioequivalent increases in TDF bioavailability over fasted
administration (Shiomi et al., 2014).
Bioavailability of TDF was increased in one study using a very high fat meal in HIV
uninfected males. Effects of a very high fat meal were evaluated during phase I testing of TDF.
Participants ingested a high fat meal (50% fat, 1000kcal) 30 minutes prior to administration of
TDF. TDF bioavailability in the fed group was increased 40% over the fasted group, and Cmax
was increased 14%. Tmax also increased from 0.5-1 h in a fasted state to 1.3-3 h in a fed state,
consistent with a slowing of gastric emptying following a meal (Barditch-Crovo et al., 2001;
Kearney et al., 2004). This same group noted that a high fat meal was not indicative of normal
diet, and studied the effects of a light meal on TDF bioavailability and found no significant
effect. According to its prescribing information, TDF can be administered with or without a
meal (Gilead Sciences, 2001). It should be noted that certain TDF fixed-dose combination
formulations such as TDF/FTC/RPV and TDF/FTC/ EVG/COBI should be taken with food due
to significant decreases in RPV (40%) and EVG (50%) bioavailability in a fasted state (German
et al., 2010; Mathias et al., 2012; Shiomi et al., 2014).
Though TDF is intended to be cleaved by plasma esterases, it is susceptible to cleavage
by intestinal carboxylesterases when administered by the oral route. It is hypothesized that this
intestinal hydrolysis and efflux via Pgp is what limits TDF bioavailability in humans (Shaw et
al., 1997; van Gelder et al., 2002; Yuan, Dahl, & Oliyai, 2001). Ester rich fruit juices such as
grapefruit, orange, cranberry, and concord grape have been shown to increase oral absorption of
drugs such as lopinavir (LPV) and saquinavir (SQV) through inhibition of Pgp, MRP-2, and
various cytochrome P450s (CYPs) (Bailey, Malcolm, Arnold, & Spence, 1998; Honda et al.,
2004; Ravi, Joseph, Avula, & Anthireddy, 2015). As TDF is a substrate of Pgp, studies were
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conducted to determine if ester rich fruit juices increase TDF bioavailability and intestinal
absorption. Strawberry juice extract increased TDF intestinal absorption in Caco-2 cell lines to
67%, while grapefruit and cranberry juice extracts increased TDF bioavailability by 97 and 24%
in an in vivo rat study (Shailender, Ravi, Saha, & Myneni, 2017; Van Gelder et al., 1999).
Additional investigation needs to be done to determine if this effect is also seen in humans.
Age Related Differences in Tenofovir Bioavailability and Pharmacokinetics
TDF is FDA approved for use in the US in children age two and older. As HIV is a
chronic disease, it is important to determine the developmentally associated changes in
pharmacokinetic parameters of antiretroviral therapy. Studies have been conducted to determine
the pharmacokinetic profile of TDF administration in neonates, children/adolescents, and adults.
TDF pharmacokinetics vary in children comparatively to adults, and these variables need to be
considered when determining dosing. Initial pharmacokinetic studies were run following TDF’s
approval for use in adults. Hazra and colleagues (2004) determined the adult-equivalent dose in
children to be ~175 mg/m2 based on calculations from initial pharmacokinetic studies in adults.
In a cohort of children ranging from 4-18 years of age given 175 mg TDF for four weeks, AUC
and Cmax were reported to be 34 and 27% lower than the equivalent dose in adults. The decrease
in AUC may be explained by the observed 1.5 times faster clearance in children (Barditch-Crovo
et al., 2001; Hazra et al., 2004).
Studies where HIV-positive children were administered a full adult dose of TDF once
daily showed similar pharmacokinetic changes observed in the initial pharmacokinetic study.
Children and adolescents (defined as <25 years old) have lower plasma concentrations of TFV
compared to adult patients and clearance in children was 36% faster, which may contribute to the
lower plasma concentration. The increase in clearance may be due to a larger kidney relative to
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body size as well as increased renal function (Baheti, King, Acosta, & Fletcher, 2013; King et
al., 2011). Additionally, Baheti and colleagues (2013) reported that children have almost 50%
higher intracellular concentrations of TDP following oral administration compared to adults.
This phenomenon may be due to a lower effective concentration, EC50 seen in children rather
than adults for TFV (100 ng/mL vs 192 ng/mL respectively).
Though no significant adverse effects were initially observed in studies using an adult
dose, studies have also been conducted to determine effective weight-band TDF dosing in
children due to concerns of bone density loss at different stages of bone dynamics. Longitudinal
assessment of available data determined that overall incidence of bone mineral density (BMD)
loss in children taking TDF at 24-32%; this loss occurs within 6-12 months of initiation of
treatment and then stabilizes (Aurpibul et al., 2015; Jacobson et al., 2010; O'Brien, Razavi,
Henderson, Caballero, & Ellis, 2001; Puthanakit et al., 2012; Schtscherbyna et al., 2012).
A study conducted in children age 9 to 18 years also saw increased TFV clearance
relative to adults, although clearance increased with body weight. Because of the differences in
clearance, this model recommends prescribing TDF to children based on weight to achieve adult
AUC: 150 mg at 20-30 kg body weight, 225 mg at 30-40 kg body weight, and the full adult dose
of 300 mg at over 40 kg bodyweight (Bouazza et al., 2011); no mention of adverse effects was
made in this study. Another study conducted based on weight-band dosing in children 3-17
years determined similar dosing parameters: 150 mg at 15-21 kg body weight, 225 mg at 22-33
kg body weight, and a full adult dose of 300 mg at >33 kg body weight. In this 96 week study,
28% of patients experienced a decrease in BMD by 24 weeks, at which point BMD remained
constant (Aurpibul et al., 2015).
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TDF is most commonly administered in children as part of a treatment regimen also
containing LPV and RTV, unlike adults who are commonly prescribed single dose combination
tablets (see previous section). It is relevant to note that LPV increases TDF AUC by 34% and
serum concentration by 30% in adults (Barditch-Crovo et al., 2001; Kearney et al., 2004). This
phenomenon is also seen in children, and is attributed to the observed 25% decrease in TDF
clearance when co-administered with LPV (Aurpibul et al., 2015; Bouazza et al., 2011). It is
recommended that TDF dosing be adjusted in children when co-administered with LPV: 150 mg
at 20-40 kg body weight, 225 mg at 40-50 kg body weight, and 300 mg at >55 kg body weight
(Bouazza et al., 2011).
TDF is approved to treat HIV in children >2 years of age in combination with other
medications. It is recommended that dosage be adjusted according to body weight in children
<12 years of age (Gilead Sciences, 2001). Additional study needs to be conducted on the
observed interaction of TDF with LPV, as well as to monitor the incidence of bone density loss
in children. Additional research is needed to evaluate the effect of age on the renal tubular
transporters and potential impact on TFV clearance. TFV is a substrate for the efflux transporter
MRP4. A study in rats reported that MRP4 expression developed slower than the basolateral
membrane transporters OAT1 and OAT3 (Nomura, Motohashi, Sekine, Katsura, & Inui, 2012).
The developmental expression of MRP4 and other transporters is an area of limited information
and may explain some of the differences related to TFV clearance with age.
Tenofovir as a Prophylactic Agent: Sex Related Differences in Pharmacokinetics
TDF is commonly used for antiretroviral pre-exposure chemoprophylaxis (PrEP) in HIVuninfected patients who engage in high risk sexual encounters. Studies evaluating oral TDF/FTC
PrEP efficacy show modest protection (76%) when taken twice a week and 75-99% infection

15

protection when taken every day. Studies using oral TDF 300 mg tablets as PrEP show a 67%
reduction in HIV incidence but high adherence was necessary (Anderson et al., 2012; Baeten et
al., 2012). It should be noted that while TFV pharmacokinetics are similar, there are
documented differences in TDP intracellular concentrations in HIV-infected and uninfected
patients; TDP concentrations are higher in HIV-infected patients (120 fmol/million cells) than in
healthy patients (42 fmol/million cells) (Anderson et al., 2012; Baheti et al., 2013). Currently,
TDF/FTC is the only FDA approved PrEP regimen; it must be taken daily in conjunction with
safer sex practices and HIV-status monitoring every three months. HIV-status monitoring is
critical as HIV-1 resistance has been documented in cases of undetected infection when using
TDF/FTC (Gilead Sciences, 2004).
To evaluate PrEP options for women, studies have been conducted to determine the
efficacy of a topical 1% TDF gel formulation in the prevention of HIV infection. The original
CAPRISA clinical trial showed modest protection, with an incidence of reduction ranging from
39-54% depending on adherence (Abdool Karim et al., 2010). TDP intracellular concentrations
were not measured. A study of PrEP regimens of TDF, TDF/FTC, or 1% TDF vaginal gel in
African women determined that there was no effect in the prevention of HIV transmission
(Marrazzo et al., 2015); again TDP concentration was not measured. Currently 1% gel TDF
formulation is not approved for PrEP, as efficacy has thus far been shown to be moderate at best.
Recently clinical studies were done to determine the differences in TFV-DP distribution
in healthy women using the TDF 1% gel, TDF 300 mg oral tablet, or both. TDP vaginal
concentration was 130-fold higher in patients using the topical gel than oral dosing, but systemic
TDP concentrations were 56-fold lower. Combination regimens of oral and topical TDF resulted
in anal tissue concentrations 3-fold higher than in groups that used the oral formulation alone
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(Burns, Hendrix, & Chaturvedula, 2015; Hendrix et al., 2013). Efficacy as a PrEP regimen was
not directly measured in this study.
The extremely high vaginal concentrations of TDP may be due in part to hormonal
regulation. Estradiol increases the amount of TDP present in isolated epithelial cells from the
female reproductive tract, progesterone has no effect, and estradiol-progesterone combination
treatment negates the stimulatory effect of estradiol. In CD4 cells isolated from the female
reproductive tract, progesterone alone and in combination with estradiol greatly reduced TDP
concentrations (Shen et al., 2014). These results suggest that hormonal regulation of TFV
phosphorylation is dependent on cell type. It has been hypothesized that women experience a 710 day window of increased susceptibility to HIV-infection due to immune suppression by sex
hormones following ovulation (Wira & Fahey, 2008). The changes in TDF-uptake and
activation in the female reproductive tract may be due to the hormonal responses seen in
previous studies.
It is worth noting that while TDP concentrations vary in the female reproductive tract,
administration of TDF with oral contraceptive pills (OCP) did not change either TFV or OCP
systemic levels (Kearney & Mathias, 2009). The observed responsiveness to sex hormones may
be limited to tissues within the reproductive tract; additional study needs to be done in this area
to fully determine the relationship between TDF pharmacokinetics and sex hormones.
TDF has also been examined in late pregnancy and labor to prevent vertical transmission
of HIV from expectant mothers to their unborn children. One study gave 300 mg TDF at the
onset of labor and to neonates within 12 h of birth to infected mothers; a 13 mg/kg neonate dose
produced intracellular TDP concentrations similar to adult levels (Hirt et al., 2011). However
plasma concentration remains low as seen in children taking TDF, and there is a delay in the
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presence of TDP in neonatal PBMCs. There was no quantifiable TDP in fetal PBMCs. The
delay in TFV phosphorylation could be due to differences in enzyme expression and activity in
neonates vs. children. Another study showed similar results: HIV-infected mothers were given a
600 mg dose of TDF and neonates were given a 6 mg/kg daily dose, resulting in plasma
concentrations similar to those seen in adults. Infant clearance was also equivalent to that seen
in older children (Mirochnick et al., 2014).
It is important to note that TDF pharmacokinetics are slightly altered during pregnancy.
During the third trimester TDF AUC is 20% lower compared to postpartum levels. This
transient difference may be directly attributable to increased weight and faster clearance during
the last trimester of pregnancy (Best et al., 2015). Additional research needs to be done to
determine changes in pharmacokinetic parameters during pregnancy, and how these changes
affect vertical HIV transmission to children.
Alternative Tenofovir Prodrug Formulations
Recently, tenofovir alafenamide (TAF) has undergone phase I-III testing and was
approved to treat chronic Hepatitis B (HBV) in 2016. TAF has greater plasma stability, more
effective cellular loading than TDF, and maintains a similar oral bioavailability at 17%. TAF
has a 50% effective concentration (EC50) of 0.005 uM rather than 5 uM seen with TDF, leading
to significantly less plasma exposure, and, by association, lower systemic side effects (Buti et al.,
2016; Lee et al., 2005; Sax et al., 2015). TAF underwent phase I-II testing in HIV patients, but
did not make it to phase III due to the risk of HIV-1 resistance (Gilead Sciences, 2017;
Markowitz et al., 2014).
TAF has been approved to replace TDF in fixed-dose combination tablets to treat HIV
following phase III trials. The combination product of TAF/FTC/COBI/EVG demonstrated 90%
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virologic success in both treatment naïve and treatment experienced patients with a lower
incidence of adverse renal and bone effects when compared to TDF/FTC/COBI/EVG (Gilead
Sciences, 2015b; Mills et al., 2016; Pozniak et al., 2016; Sax et al., 2015; Wohl et al., 2016).
The combined preparation TAF/FTC demonstrated 93% virologic success when compared to the
combination of TDF/FTC, with no documented renal tubulopathy in either test group. It should
be noted that while TDF/FTC is recommended as a PrEP regimen, TDF/FTC is not approved for
PrEP regimen by the FDA as of May 2017 (Gallant et al., 2016; Gilead Sciences, 2015a; Mills et
al., 2016; Sax et al., 2015). While TDF is currently FDA approved for HIV-1 treatment in
patients two years of age and older, TAF fixed dose combinations are only indicated for patients
greater than 12 years of age.
The use of liposomes and niosomes has been investigated to improve the bioavailability
of TDF. When encapsulated in a liposome made of phospholipids and 7.5% cholesterol, TDF
had an increased permeability rate across Caco-2 cells (3.71E-07 cm/s) compared to TDF alone
(4.18E-07 cm/s) (Spinks, Zidan, Khan, Habib, & Faustino, 2017). When encapsulated in a
niosome created with sorbitan monoesterate in a 1:1 ratio, >99% of the TDF dose was released in
vitro within 24 h. In a subsequent in vivo study in rats, TDF AUC was increased two-fold when
encapsulated in a niosome compared to TDF alone; Cmax, T1/2, and Tmax were also increased,
possibly due to increased GI absorption and the release retarding effects of niosomes (Azmin et
al., 1985; Kamboj, Saini, & Bala, 2014). No studies have yet been conducted to determine if
liposomes or niosomes are more efficient in improving TDF bioavailability or if encapsulation is
effective in humans for the treatment of HIV using TDF.
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Conclusions
TDF is the prodrug for TFV, which is a nucleotide analogue reverse transcriptase
inhibitor that is very effective in the treatment of HIV and chronic HBV. TDF has a favorable
pharmacokinetic profile, allowing for once a day dosing, and its pharmacokinetics are largely
unchanged when given in fixed-dose combination tablets. TDF has been shown to be effective
as a prophylactic agent to prevent HIV-1 transmission, leading to site-specific formulations; this
area of research remains highly active. TDF does have limited oral bioavailability, and research
is ongoing to determine if bioavailability can be increased. More importantly, TDF improves
intracellular concentration in PBMCs. Overall, TDF remains one of the first line agents in the
treatment of HIV and HBV providing once daily dosing which improves patient compliance.
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CHAPTER 2
TENOFOVIR INDUCED NEPHROTOXICITY: THE SCOPE OF THE CURRENT
WORK
Tenofovir Induced Nephrotoxicity
TDF is the prodrug for TFV which is a nucleotide analogue reverse transcriptase inhibitor
that is approved in the United States for the treatment of HIV and chronic Hepatitis B. TDF has
a favorable pharmacokinetic profile, allowing for once a day dosing and has limited incidence of
day to day adverse effects; both of these factors are important to increase compliance in chronic
disease treatment (Barditch-Crovo et al., 2001). TDF is also effective in both treatment naïve
and treatment experienced patients, particularly in patients who have developed HIV-1
resistance (Miller et al., 2001; Squires et al., 2003). These attributes make TDF a first line agent
in the treatment of HIV according to the World Health Organization.
Despite its many positive attributes, renal toxicity is an adverse effect associated with
TDF use clinically. TFV can induce reductions in GFR and free calcitriol, increases in serum
creatinine and plasma vitamin D binding, renal failure, and in extreme cases Fanconi Syndrome.
Fanconi syndrome is described as a renal tubular function disorder that results in excess
excretion of phosphate salts, protein, potassium, glucose, and urate (Del Palacio et al., 2012; Hall
et al., 2011; Havens et al., 2013). Clinical studies indicate that the mitochondria of the proximal
tubules are the target of TFV induced toxicity as shown by enlarged and malformed
mitochondria in electron microscopy cross sections (Cote et al., 2006; Hall et al., 2011; Herlitz et
al., 2010; Woodward et al., 2009). Proximal tubular mitochondrial toxicity has also been
described in mice and rats treated with TFV as shown by disruptions in mitochondrial cristae and
a reduction in mtDNA levels (Kohler et al., 2009; Lebrecht et al., 2009).
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Renal excretion requires both glomerular filtration and tubular secretion. Following
glomerular filtration, TFV is transported from blood into proximal tubular epithelial cells by
organic anion transporters 1 and 3 (OAT1, OAT3, respectively) (Kohler et al., 2011; Uwai, Ida,
Tsuji, Katsura, & Inui, 2007). TFV can then undergo tubular secretion into the lumen via the
multidrug resistant proteins 2 (MRP2) and 4 (MRP4) (Izzedine, Launay-Vacher, & Deray, 2005;
Kohler et al., 2011). While there is knowledge of the mechanisms contributing to tubular
transport, the mechanism of TFV-associated proximal tubule damage is not extensively known at
this time. This lack of knowledge is due largely to limited experimental models.
HK-2 Cell Model
Mechanistic studies require a model that is consistent with what occurs in humans. The
selection of suitable models to study TFV cytotoxicity has been problematic as most in vivo
models require subchronic treatment of animals. TFV toxicity in rodents such as rats has
required eight weeks of daily treatment in order to develop nephrotoxicity (Lebrecht et al.,
2009). In this study, rats treated for eight weeks exhibited diminished renal function and
proximal tubular damage along with enlarged mitochondria. Another study showed that
treatment for five weeks with TFV induced oxidative stress in Wistar rats dosed with very high
levels of TFV (Abraham, Ramamoorthy, & Isaac, 2013).
An in vitro model was first reported by Wang and Flint (2013) that developed TFV
cytotoxicity using primary human kidney cells (Wang & Flint, 2013). Primary human kidney
cells required culturing for 19 days with 200 μM TFV to induce cytotoxicity, which was a long
duration at concentrations higher than pharmacological levels. The need for higher
concentrations of TFV to induce toxicity in primary proximal tubule cell lines may be due to
differences in OAT1 and OAT3 expression. Endogenous expression of OAT1 and OAT3 in
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primary human proximal tubule cells has been shown to vary greatly from sample to sample
(Lash, Putt, & Cai, 2006) and TFV-induced cytotoxicity is dependent on OAT1 and OAT3
expression (Kohler et al., 2011; Nieskens et al., 2016).
Renal toxicity was diminished in OAT1 knockout mice, indicating that OAT1 has a
primary contribution to TFV renal uptake into proximal tubular epithelial cells (Kohler et al.,
2011). In vitro studies reported that HEK293 cells transfected with OAT1 were much more
sensitive to TFV cytotoxicity than cells transfected with OAT3 (Izzedine et al., 2005); further,
intracellular TFV concentrations were higher in HEK-OAT1 transfected cells compared to wild
type and these findings support the concept that OAT1 is important for TFV uptake.
Human Kidney 2 (HK-2) cells were selected as a model to investigate the in vitro
cytotoxicity of TFV. HK-2 cells are an immortalized, noncancerous, human epithelial proximal
tubular cell line that maintains activity and biochemical properties similar to in vivo proximal
tubule cells (Gunness, Aleksa, Kosuge, Ito, & Koren, 2010; Paolicchi et al., 2003; Ryan et al.,
1994). HK-2 cells express OAT1 and OAT 3, which are necessary to transport TFV into
proximal tubule cells as well as multidrug resistance protein 4 (MRP4), which is necessary for
efflux from the proximal tubule cell (Miyamoto et al., 2012). HK-2 cells are commonly used to
study drug toxicity and in mechanistic studies as they eliminate potential species differences that
occur in porcine, dog, and mouse cell lines (Andreucci et al., 2015; Gunness et al., 2010; Jia, Ha,
Yang, Chang, & Yang, 2011; Kondo, Inamura, Matsumura, & Matsuoka, 2012). This thesis
establishes that HK-2 cells are a viable model to study TFV induced cytotoxicity as well as
utilize them to gain insight into the mechanism of this toxicity.
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Statement of Hypothesis
Current published studies have determined that TFV induces damage to proximal tubule
epithelial cells. The purpose of my dissertation was to investigate a mechanistic understanding
of TFV induced cytotoxicity and investigate potential methods to mitigate or prevent it. To that
end, I tested the following hypotheses in this work. First, TFV is toxic to HK-2 cells at clinically
relevant concentrations. Second, the mechanism of this toxicity is due to oxidative stress and
mitochondrial dysfunction. Lastly, pretreatment with antioxidants mitigates TFV induced
cytotoxicity.
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Abstract
Tenofovir (TFV) is an antiviral drug approved for treating Human Immunodeficiency
Virus (HIV) and Hepatitis B. TFV is administered orally as the prodrug tenofovir disoproxil
fumarate (TDF) which then is deesterified to the active drug TFV. TFV induces nephrotoxicity
characterized by renal failure and Fanconi Syndrome. The mechanism of this toxicity remains
unknown due to limited experimental models. This study investigated the cellular mechanism of
cytotoxicity using a human renal proximal tubular epithelial cell line (HK-2). HK-2 cells were
grown for 48 h followed by 24 to 72 h exposure to 0–28.8 µM TFV or vehicle, phosphate
buffered saline (PBS). MTT (MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide) and Trypan blue indicated that TFV diminished cell viability at 24–72 h. TFV
decreased ATP levels at 72 h when compared to vehicle, reflecting mitochondrial dysfunction.
TFV increased the oxidative stress biomarkers of protein carbonylation and 4-hydroxynonenol
(4-HNE) adduct formation. Tumor necrosis factor alpha (TNFα) was released into the media
following exposure to 14.5 and 28.8 µM TFV. Caspase 3 and 9 cleavage was induced by TFV
compared to vehicle at 72 h. These studies show that HK-2 cells are a sensitive model for TFV
cytotoxicity and suggest that mitochondrial stress and apoptosis occur in HK-2 cells treated with
TFV.
Introduction
Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor that is
approved in the United States to treat Human Immunodeficiency Virus (HIV) and chronic
Hepatitis B. Tenofovir (TFV) is administered as the prodrug TDF; TDF was designed to improve
the bioavailability of TFV by the addition of 2-methyl carbonate esters which are deesterified to
the active drug TFV (Shaw et al., 1997). TFV is efficacious to both treatment-naïve and
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treatment-experienced patients and has been beneficial in patients that have acquired resistance
to other HIV medications (Dore et al., 2004; Miller et al., 2001). TFV is considered a first line
agent essential for treatment of HIV by the World Health Organization. TFV is the only
antiretroviral that is a nucleotide analogue reverse transcriptase inhibitor. Compliance is higher
with TFV than with other antiretroviral agents due to fewer side effects and once daily dosing
(Barditch-Crovo et al., 2001).
Despite many positive therapeutic attributes, an adverse effect of TFV is nephrotoxicity.
TFV-induced nephrotoxicity is characterized by a decreased glomerular filtration rate (GFR),
increased serum creatinine, renal failure, and Fanconi-like Syndrome (Del Palacio et al., 2012;
Hall et al., 2011). Fanconi Syndrome is a proximal tubular transport abnormality associated with
impaired tubular reabsorption resulting in excess glucose, protein, urate, and phosphate
excretion.
Renal excretion requires both glomerular filtration and tubular secretion. TFV is
transported from blood into proximal tubular epithelial cells by organic anion transporters 1 and
3 (OAT1, OAT3, respectively) (Kohler et al., 2011; Uwai et al., 2007). Renal toxicity was
diminished in OAT1 knockout mice, indicating that OAT1 has a primary contribution to TFV
renal uptake into proximal tubular epithelial cells (Kohler et al., 2011). In vitro studies reported
that HEK293 cells transfected with OAT1 were much more sensitive to TFV cytotoxicity than
cells transfected with OAT3 (Zhang, Piotrowski, Zhang, Leach, 2015); further, intracellular TFV
concentrations were higher in HEK-OAT1 transfected cells compared to wild type and these
findings support the concept that OAT1 is important for TFV uptake. The drug can then undergo
tubular secretion into the lumen via the multidrug resistant proteins 2 (MRP2) and 4 (MRP4)
(Izzedine et al., 2005; Kohler et al., 2011). While there is knowledge of the mechanisms
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contributing to tubular transport, the mechanism of TFV-associated proximal tubule damage is
not extensively known at this time. This knowledge gap is due largely to limited experimental
models; in vivo studies have used TFV treatment for three to eight weeks (Lebrecht et al., 2009;
Ramamoorthy, Abraham, & Isaac, 2014), or primary renal cells exposed for up to 22 days (Vidal
et al., 2006). The long duration of these experiments is not ideal and can hamper mechanistic
studies. Additionally, daily treatment of rats for an extended period can cause significant stress,
adding other complications to a mechanistic study. Cell lines can circumvent the contribution of
stress as well as eliminate extrarenal factors and hemodynamics.
The purpose of this study was to explore the in vitro cytotoxicity of TFV in HK-2 cells.
We selected Human Kidney 2 (HK-2) cells as a model as these cells are an adult, noncancerous,
immortalized human epithelial cell line. HK-2 cells maintain biochemical properties and activity
similar to in vivo proximal tubule cells (Gunness et al., 2010; Paolicchi et al., 2003; Ryan et al.,
1994). Additionally, HK-2 cells express OAT1 and OAT3 proteins (Miyamoto et al., 2012),
which facilitate TFV transport into proximal tubule cells.
In this manuscript, we demonstrate that the HK-2 cell is a viable model to study TFVinduced cytotoxicity at clinically relevant concentrations. Further, these studies revealed that
oxidative stress, induction of apoptosis, and mitochondrial decline in ATP are associated with
TFV renal cytotoxicity.
Results
TFV Effects on Cell Viability
Based on the MTT (MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide)) assay, TFV reduced cell viability within 24 h (p < 0.05) at all tested concentrations
(Figure 4). MTT values continued to show diminished cell viability at 48 and 72 h (p < 0.001)
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for all TFV concentrations when compared to vehicle control (Figure 4). TFV final
concentrations of 4.75 and 14.5 µM showed additional decline in cell viability at 72 h compared
to other treatment groups (p < 0.05) (Figure 4). Trypan blue exclusion and cell counts were
conducted in order to confirm that the TFV mediated decline in formazan formation could not be
attributed to a direct effect of TFV on mitochondrial reductase enzymes converting MTT to
formazan. Trypan blue cell counts (Figure 5) confirmed that TFV diminished cell viability
beginning at 24 h and continuing for 72 h when compared to vehicle control. There was no
difference in cell viability between groups. IC50 values calculated using MTT data were 9.21
and 2.77 µM TFV at 48 and 72 h, respectively. MTT viability studies conducted with the less
nephrotoxic antiviral agent, abacavir, indicated that abacavir did not reduce cell viability at 24 h
(Figure 4D) suggesting that our model is an appropriate model to examine nephrotoxic agents.
Further experiments were initiated with TFV to explore the cellular mechanism of TFV
cytotoxicity.
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Figure 4. Tenofovir cytotoxic effects on cell viability in HK-2 cells using MTT. Tenofovir
diminished cell viability at 24 (A), 48 (B) and 72 h (C). Statistical difference from 0 μM
tenofovir depicted in (A and B) by asterisks (* p < 0.05, *** p < 0.001). Different superscript
letters (C) indicate groups that are different from each other (p < 0.05); (D) depicts cell viability
following exposure for 24 h to another antiviral agent, abacavir. Abacavir did not alter viability
at the concentrations tested. Each bar represents Mean ± SEM for three independent experiments
run with two biological replicates.
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Figure 5. Tenofovir cytotoxic effects on cell viability in HK-2 cells using Trypan Blue
Exclusion. Tenofovir diminished cell viability at 24 (A), 48 (B) and 72 h (C). Statistical
difference from 0 μM tenofovir is denoted by asterisks (*** p < 0.001). Each bar represents
Mean ± SEM for three independent experiments run with two biological replicates.

TFV Effects on Mitochondrial Function
Our hypothesis was that TFV impairs mitochondrial function resulting in decreased ATP
levels. ATP levels were unchanged compared to vehicle by TFV after 24 or 48 h incubation
(Figure 6). ATP levels were diminished by all concentrations of TFV at 72 h when compared to
vehicle (p < 0.001) (Figure 6). These results suggest that multiple mechanisms of cytotoxicity
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may be induced by TFV since the reduction in ATP levels was not apparent prior to a reduction
in cell viability.

Figure 6. Tenofovir effects on ATP levels in HK-2 cells. ATP levels were measured following
24 (A), 48 (B) and 72 h (C) exposure to tenofovir. ATP was measured using an ATP Assay kit
(Biovision) and simultaneously run ATP standards. Statistical difference from 0 μM tenofovir
denoted by asterisks (*** p < 0.001). ATP levels at 24 and 48 h represent Mean ± SEM for two
independent experiments run with three biological replicates. ATP levels at 72 h represent Mean
± SEM for four independent experiments run with three biological replicates.

TFV Effects on Oxidative Stress
TFV increased oxidative stress as shown by Oxyblot analysis at 72 h relative to control in
groups treated with 14.5 and 28.8 μM TFV (p < 0.001, Figure 7). Protein carbonylation was not
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increased relative to control at 48 h or at lower TFV concentrations at 72 h. 4-HNE adduct
formation was increased following 72 h exposure for treatment groups of 3.0 to 28.8 μM TFV
(Figure 8). TNFα secretion into the media was increased at 72 h exposure to TFV compared to
vehicle (p < 0.001). TNFα expression in cell lysate was decreased at 48–72 h (p < 0.05) as
shown by Western blot (Figure 9). These results suggest that TNFα is released into the media as
TFV cytotoxicity occurs and that TFV does not increase TNFα protein expression. TNFα
expression in the TFV treated cells was similar to vehicle control at 24 h when cell viability was
diminished. These results suggest that it is unlikely that TNFα is the primary event in the
mechanism of TFV cytotoxicity but rather occurs as a result of initial toxicity. The subcellular
generation of oxidative stress may be due to mitochondrial damage, as ATP levels were also
diminished by TFV. It is still not clear if TFV directly damages the mitochondria, leading to
oxidative stress, or if TFV induces reactive oxygen species that subsequently damage
mitochondria; additional studies are needed to further explore the mechanism of cytotoxicity.
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Figure 7. Tenofovir treatment for 72 h increased protein carbonylation in HK-2 cells.
Protein carbonylation was measured in HK-2 cell lysate following 48 (A) and 72 h (B) exposure
to TFV. Representative gel and cumulative densitometry included in each panel. Representative
blot with MemCode Reversible staining for equal 25 μg protein loading and cumulative protein
densitometry depicted for 48 (C) and 72 h (D) exposure. Asterisks (** p < 0.01, *** p < 0.001)
indicate statistical difference from the vehicle control group. Each bar represents Mean ± SEM
for three independent experiments run with three biological replicates.
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Figure 8. Tenofovir effects on 4-HNE adduct formation in HK-2 cells. 4-HNE adduct
formation was measured in HK-2 cell lysate following 48 h (A) and 72 h (B) exposure to TFV.
Representative gels and cumulative densitometry included in each panel. Representative blot
with MemCode Reversible staining for equal 40 μg protein loading and cumulative protein
densitometry depicted for 48 h (C) and 72 h (D) exposure. Asterisks (* p < 0.05, *** p < 0.001)
indicate statistical difference from the vehicle control group. Each bar represents Mean ± SEM
for three independent experiments run with three biological replicates.
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Figure 9. TNFα expression in HK-2 cell lysate and media following tenofovir exposure. (A)
TNFα release into media expressed as a percent of control following 24, 48, and 72 h TFV
exposure. TNFα in media was increased following a 72 h exposure for all concentrations relative
to control (*** p < 0.001). (Panel B) provides representative blot and cumulative densitometry
for TNFα expression in cell lysate following 24, 48, 72 h TFV exposure. Statistical difference
from 0 μM tenofovir depicted by asterisk (* p < 0.05); (C) depicts cumulative densitometry and
representative blots for 50 μg protein loading of cell lysates visualized with MemCode
Reversible Protein staining. Each bar represents Mean ± SEM for two independent experiments
run with three biological replicates.

TFV Effects on Apoptosis Initiation
TFV increased cleaved caspase 3 (p < 0.0.05) and cleaved caspase 9 relative to control
for all treatments at 72 h exposure (Figure 10). Caspase 8 expression was measured after 48 and
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72 h exposure to TVF. TFV did not increase caspase 8 cleavage relative to control at either time
point. Cleaved caspase 8 was minimal in all groups and was decreased by higher TFV treatment
relative to vehicle control. These results suggest that the increase in TNFα in the media at 72 h
was not sufficient to stimulate caspase 8 cleavage. These data show that TFV induces apoptosis
in HK-2 cells, and that apoptosis is induced via mitochondrial damage.

Figure 10. Cont’d.

37

Figure 10. Tenofovir effects on the expression of cleaved caspase 3, 8 and 9 in HK-2 cells.
Representative blot and cumulative densitometry for cleaved to total caspase 9 (A), caspase 3 (B)
and caspase 8 (D) protein expression following 72 h. Asterisks (* p < 0.05, ** p < 0.01, *** p <
0.001) indicate statistical difference from the vehicle control group; (C) Depicts 48 h caspase 8
cleavage. (E) representative blots of MemCode reversible staining for 40 μg protein loading and
cumulative densitometry; blots and densitometry depicted (from left to right) are for (A) (72 h
Caspase 3), (B) (72 h Caspase 9), (C) (48 h Caspase 8), and (D) (72 h Caspase 8). Each bar
represents Mean ± SEM for three independent experiments run with three biological replicates.

Ascorbic Acid Protection of TFV Cytotoxicity
Oxidative stress was increased by TFV resulting in increased protein carbonylation
(Figure 4) and increased 4-HNE protein adduction (Figure 5) suggesting that a rise in reactive
oxygen species occurs with TFV cytotoxicity. Pretreatment with ascorbic acid reduced TFV
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toxicity in HK-2 cells (Figure 11) as cell viability was higher in cells exposed to TFV in the
presence of ascorbic acid compared to TFV alone. These findings suggest that an antioxidant can
reduce TFV cytotoxicity in HK-2 cells.

Figure 11. Effects of ascorbic acid on tenofovir cytotoxicity. Ascorbic acid did not alter cell
viability relative to vehicle control. Ascorbic acid protected HK-2 cells from tenofovir
cytotoxicity as assessed by MTT viability. An asterisk (* p < 0.05) indicates statistical difference
from all other groups. Values represent Mean ± SEM for three independent experiments run with
three biological replicates.

Discussion
TFV is a very effective antiviral nucleotide reverse transcriptase inhibitor prescribed
worldwide in the treatment of HIV and Hepatitis B. Patients treated with TFV have an increased
incidence of renal impairment (Fux et al., 2007; Verhelst et al., 2002). Renal TFV toxicity in
humans is characterized by Fanconi Syndrome, and depending on the dose, development of
irreversible impaired renal function. There is a positive correlation between increased TFV

39

plasma concentration, renal toxicity and the duration that patients were treated with TFV Ezinga
et al., 2014; Quesada et al., 2015) because treatment with TFV is chronic, examination of the
mechanism of renal toxicity is clinically relevant. Understanding the mechanism is essential for
the development of methods to mitigate TFV renal impairment.
Mechanistic studies require a model that is consistent with what occurs in humans. The
selection of suitable models to study TFV cytotoxicity has been problematic as most in vivo
models require subchronic treatment of animals. TFV toxicity in rodents such as rats has
required eight weeks of daily treatment in order to develop nephrotoxicity (Lebrecht et al.,
2009). In this study, rats treated for eight weeks exhibited diminished renal function and
proximal tubular damage along with enlarged mitochondria. Another study showed that
treatment for five weeks with TFV induced oxidative stress in Wistar rats dosed with very high
levels of TFV (Abraham et al., 2013).
An in vitro model was first reported by Wang and Flint (2013) that developed TFV
cytotoxicity using primary human kidney cells (Wang & Flint, 2013). Primary human kidney
cells required culturing for 19 days with 200 μM TFV to induce cytotoxicity, which was much
longer and at concentrations higher than pharmacological levels. The need for higher
concentrations of TFV to induce toxicity in primary proximal tubule cell lines may be due to
differences in OAT1 and OAT3 expression. Endogenous expression of OAT1 and OAT3 in
primary human proximal tubule cells has been shown to vary greatly from sample to sample
(Lash, Putt, & Cai, 2006) and TFV-induced cytotoxicity is dependent on OAT1 and OAT3
expression (Kohler et al., 2011; Nieskens et al., 2016). Our HK-2 cell model is more sensitive
than human primary proximal tubule cells as we have shown induction of cytotoxicity in 24 h
compared to 22 days and at a concentration almost ten times lower than reported for human
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primary proximal tubular epithelial cells (Vidal et al., 2006). In addition to inducing cytotoxicity
at 24 h, our HK-2 cell model has an IC50 of 9.2 μM TFV at 48 h, and an IC50 of 2.77 μM TFV at
72 h. Other cell types such as HEK293 cells have been used to study tenofovir cytotoxicity, but
appear less sensitive than our HK-2 model. One study showed that TFV-induced cytotoxicity
within 48 h in HEK293 cells transfected with OAT1; however, the IC50 was reported to be 316
μM (Zhang et al., 2015).
Our study is the first to show that HK-2 cells can be used to evaluate TFV cytotoxicity.
TFV renal cytotoxicity was evident within 24 h at clinically relevant concentrations. Primary
human kidney cells required a concentration of 200 μM, which is higher than reported maximal
clinical steady state plasma concentration (Wang & Flint, 2013). In comparison, in our study,
viability was diminished in HK-2 cells with TFV concentrations ranging from 1.5 to 28.8 μM.
The concentrations used in our current study are clinically relevant as plasma TFV
concentrations have been reported to be 2.2 μM in HIV-1 infected patients (Barditch-Crovo et
al., 2001; Zhang et al., 2015). Additionally, TFV plasma concentrations are higher in HIV-1
patients and non-infected individuals with existing renal impairment; patients with renal
impairment also experience a longer duration of TFV exposure, as shown by a 15-fold increase
in AUC0–24 h ( Custodio et al. 2016; Ezinga et al. 2014; Sentenac, Fernandez, Thuillier, Lechat,
and Aymard, 2003). Therefore, HK-2 cells provide a model that can be used to examine the
mechanism of toxicity without the compounding physiological parameters influencing the
response of the kidney to a toxicant. Our studies further showed that HK-2 cells can differentiate
the toxicity of different antiviral agents as abacavir, an agent that is considered less toxic to the
kidney which was not toxic in our system (Figure 4D).
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It is probable that TFV renal cytotoxicity involves multiple mechanisms and that these
mechanisms are not yet fully understood. TFV treatment of HK-2 cells decreased ATP levels
when compared to control at 72 h exposure (Figure 6). Diminished ATP levels can be mediated
by numerous pathways, including alterations in mitochondrial DNA stability, impaired
mitochondrial function, or increased oxidative stress.
Mitochondrial function relies on many factors, including the stability and integrity of
mitochondrial DNA (mtDNA). Decreased mtDNA could result in a decline in cellular ATP
levels. There are conflicting reports regarding the effects of TFV on mtDNA. The differences
may be due to species variation and differences in experimental models. For example, TFV
diminished mtDNA in HIV-1 transgenic mice (Kohler et al., 2009) while a 19 day exposure of
human primary renal proximal tubule cells to 2 and 200 μM TFV showed no change in mtDNA
compared to control (Paolicchi et al., 2003; Wang & Flint, 2013). However, effects of TFV on
mtDNA may vary between renal and nonrenal cells (Wang & Flint, 2013). Additionally, mtDNA
was diminished in human primary proximal tubule cells by another nucleoside reverse
transcriptase inhibitor, adefovir, within nine days of incubation with TDF (Wang & Flint, 2013),
indicating that TFV may be a weaker inhibitor of DNA polymerase gamma.
TFV increased expression at 72 h of cleaved caspase 3 and 9 in HK-2 cells (Figure 10).
Apoptosis can be induced via many pathways, including extracellular signals and mitochondrial
dysfunction. Each pathway activates different initiator caspase proteins; for example, cleavage of
caspase 9 occurs when mitochondrial damage initiates the intrinsic apoptotic pathway. Initiator
caspases then interact with other cellular proteins, forming an apoptosome that cleaves
executioner caspases such as caspase 3 and activates the induction of cell death. The increased
expression of cleaved caspase 3 and 9 in HK-2 cells treated with TFV indicated that apoptosis
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was occurring, and that mitochondrial dysfunction may be a major contributing factor to loss of
cell viability (Figure 10).
The renal proximal tubular epithelial cell has a high requirement for ATP generation to
maintain normal cellular processes such as active transport. The decline in cellular ATP levels
caused by TFV would impair normal proximal tubular epithelial cell function. TFV increased
oxidative stress, as protein carbonylation was elevated at 72 h exposure to 14.5 and 28.8 μM
TFV (Figure 7). The HK-2 cells were more sensitive to TFV and displayed increased oxidative
stress at clinically relevant concentrations as compared to previously examined models. A five
week treatment of rats with 12 times higher dose than what is clinically used reported a 25%
increase in renal protein carbonylation (Abraham et al., 2013); the HK-2 cells demonstrated a
much greater increase in protein carbonylation within a shorter time period than reported in vivo
treatment of rats (Figure 7), suggesting that HK-2 cells may be a more sensitive model to
examine TFV cytotoxicity.
TNFα is a proinflammaotry cytokine which is expressed in proximal tubular epithelial
cells. TNFα can be secreted from cells to induce an inflammatory response as a protective
mechanism during initial exposure to toxicants (Gu, Xing, Xu, & Lu, 2016). TNFα expression
can induce reactive oxygen species generation via mitochondria and through activation of
NADPH oxidase (Morgan, 2010). Mitochondrial damage and generation of reactive oxygen
species can stimulate the release of various cytokines including TNFα (Mittal, Siddiqui, Tran,
Reddy, & Malik, 2014). These changes in TNFα expression and secretion can modulate various
parts of the cellular antioxidant system and directly increase the production of mitochondrial
reactive oxygen species through damage to the electron transport chain. In experiments involving
exposing HK-2 cells to toxicants and/or ischemic injury, TNFα levels rose along with many
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other markers of toxicity, including increases in oxidative stress via dysfunction of cellular
antioxidant systems, activation of an inflammatory response and associated proteins, and
induction of programmed cell death (Gong, Ivanov, Davidson, & Hei, 2015; Zager, Johnson, &
Geballe, 2007; Zhang et al., 2013). We examined TNFα as a potential indicator of oxidative
stress. Our study showed that TNFα was released into the media at 72 h, while tissue showed a
decline in expression at 48 and 72 h (Figure 9). Because TNFα expression was unaltered at 24 h
(Figure 9) it is unlikely that activation of inflammatory response is the cause of the oxidative
stress observed. The decline in TNFα in the cells is consistent with loss from cells into the
media; TNFα released into the media may contribute to greater oxidative stress. Further studies
need to explore the cellular mechanism for increased oxidative stress, TNFα secretion in HK-2
cells, specifically, evaluation of mitochondrial alterations that may mediate either a decline in
mitochondrial function or increased reactive oxygen species.
Methods
Chemicals and Reagents
TFV was purchased from Cayman Chemicals (Item No. 13874, Ann Arbor, MI, USA)
and was used for all studies. The vehicle for cell treatments was phosphate buffered saline
(Invitrogen, Carlsbad, CA, USA, Item No. 14175095). MTT and other chemicals were purchased
from Sigma Aldrich (St. Louis, MO, USA) or Fisher Scientific (Pittsburg, PA, USA). Antibodies
and kits were purchased as indicated in the sections below.
Cell Lines and Tenofovir (TFV) Treatment
Human immortalized epithelial HK-2 cells were purchased from the American Type
Culture Collection (ATCC) and were cultured according to ATCC guidelines. Briefly, cells were
grown in a keratinocyte-free media with 50 μg/mL bovine pituitary extract and 5 ng/mL
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recombinant epithelial growth factor from Invitrogen (Carlsbad, CA, USA, Item No. 17005-042).
Cells were grown in a warm humidified incubator with constant settings of 37 °C and 5% CO2.
HK-2 cells were plated into six-well tissue culture plates (750,000 cells/mL) (Corning, Sigma
Aldrich Item No. CLS3516) and allowed to grow for 48 h. Media was replaced and cells were
treated with a final concentration of 0, 1.5, 3.0, 4.75, 14.5, or 28.8 μM TFV for 24, 48, or 72 h.
The vehicle was an equal volume of phosphate buffered saline (PBS). Abacavir was prepared in
sterile water and cells were treated for 24 h with 0, 1.5, 3 or 6 μM of abacavir to evaluate renal
sensitivity to an agent recognized to be less nephrotoxic. Following the treatment period, cells
were collected with Trypsin-EDTA (0.25%) (Invitrogen, Item No. 25200072) for sample
analysis.
Cell Viability
Cells were plated into 48-well tissue culture plates (39,000 cells/mL) (Cyto One, USA
Scientific, Ocala, FL, USA, Item No. CC7682-7548) and allowed to grow for 48 h followed by
treatment with vehicle or TFV. Following the treatment period, cell viability was assessed using
the MTT assay (Humphrey, Cole, Pendergrass, & Kiningham, 2005). The MTT assay relies on
the conversion of tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (Sigma Aldrich, Item No. M5655-5X1G) to formazan by NAD(P)H-dependent
oxidoreductases.
To ensure that results of the MTT Assay were not due to mitochondrial damage rather
than cell death, a trypan blue exclusion test was run based on a previously published protocol. In
brief, an aliquot of collected cells are diluted 1:10 with 40% w/v Trypan Blue solution (Sigma
Aldrich, Item No. T6146). The suspension was mixed via pipetting and allowed to sit for
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approximately 2 min. A 10 μL aliquot of suspension was transferred to a hemocytometer and
total cells, live cells, and dead cells were manually counted.
ATP Measurement
ATP levels were assessed using the ADP/ATP Ratio Bioluminescence Assay Kit
(Biovision Inc., Milpitas, CA, USA, Item No. K255-200). Briefly, 100 μL of reaction mix was
plated into a 96-well plate (Corning, Sigma Aldrich, Item No. 356519) and allowed to establish a
baseline during a 2 h room temperature incubation. A 10 μL aliquot of the sample was added to
each well and bioluminescence was measured using a luminometer. Immediately following the
measurement, 10 μL of diluted ADP-converting enzyme was added and bioluminescence was
measured again. Lysate concentration of ATP and ADP was determined using a standard curve.
Western Blot
Western blot analysis was conducted to assess the expression of active caspase 3, 8 and 9
and the formation of 4-hydroxy-2-nonenal (4-HNE) protein adducts. Protein concentration in
each sample was determined using the Bradford protein assay (Bradford, 1976). A 40 µg aliquot
of each sample was denatured by boiling for five min. Proteins were then separated on a 12.5%
polyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA,
Item No. 1620115); successful transfer and protein loading were verified using MemCode
Reversible Protein Stain Kit (Pierce Biotechnology, Rockford, IL, USA, Fisher Scientific, Item
No. PI-24580). Membranes were blocked using either a 5% w/v milk/TBST solution (10 mM
Tris-HCl, 150 mM NaCl, 0.1% Tween-20; pH 8.0) or a 1% Bovine Serum Albumin
(BSA)/TBST solution for 1 h. Membranes were next incubated with continual shaking overnight
at 4 ◦C with a rabbit polyclonal antibody for caspase 3 (1:1000 dilution, Cell Signaling
Technology, Danvers, MA, USA, Item No. 9662), caspase 8 (1:400 dilution, Biovision Inc., Item
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No. 3020-100), caspase 9 (1:1000 dilution, Cell Signaling Technology, Item No. 9502) or 4HNE (1:1000 dilution, Cell Bio Labs Inc., San Diego, CA, USA, Item No. STA-035) diluted in
5% milk/TBST or 1% BSA/TBST. The membranes were washed four times with TBST and goat
anti-rabbit HRP-linked secondary antibodies were diluted to 1:5000 in 5% milk/TBST and added
for 1 h. Membranes were washed again with TBST and then developed using Amersham ECL
Western Blotting Detection Agent (GE Healthcare Life Sciences, Marlborough, MA, USA, Item
No. RPN2232). A BioRad chemic-doc system was used to capture the gel image and used for
densitometry analysis.
Oxidative Stress
In addition to 4-HNE adduction of protein, another indicator of oxidative stress is
protein carbonylation, which can produce an aldehyde or ketone side chain on amino acids.
Protein carbonylation was analyzed using the Oxyblot Protein Oxidation Detection Kit (EMD
Millipore, Billerica, MA, USA, Item No. S7150). Following treatment for 24–72 h with vehicle
or TFV, cells were pelleted, rinsed with 500 µL PBS, and centrifuged. The pellet was then
disrupted with lysis buffer. Protein content was measured, and a 25 µg aliquot was derivatized as
previously described (Terneus, Kiningham, Carpenter, Sullivan, & Valentovic, 2007). Protein
carbonyl moieties on amino acids generated by oxidative stress are derivatized in the presence of
2,4-dinitrophenylhydrazine to stable 2,4-dinitrophenylhydrazone groups. The primary antibody
recognizes 2,4-dinitrophenylhydrazone groups on proteins and was used at a dilution of 1:150.
Protein loading was verified using the MemCode Protein Stain and results were analyzed with
BioRad Chemidoc densitometry software (version 4.0.1, Catalog No. 170-9690, BioRad,
Hercules, CA, USA). A series of studies examined whether ascorbic acid, an antioxidant, could
provide protection from TFV. HK-2 cells were allowed to grow for 48 h followed by a one h
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pretreatment with 0 or 10 µM ascorbic acid in sterile water followed by a 24 h incubation with 0
or 14.5 µM TFV. Viability of cells was assessed using the MTT assay. All media and MTT was
removed from the cells prior to the addition of DMSO to prevent any interaction of ascorbic acid
with formazan.
TNFα in Cell Media and Cell Lysate
Proximal tubular epithelial cells express TNFα. TNFα expression was measured in cell
culture media using an ELISA assay kit and in cell lysate by Western blot. Release of TNFα into
the cell culture media was measured using an ELISA kit (Abcam, Cambridge, MA, USA, Item
No. ab181421) per the manufacturer’s instructions. Briefly, 50 µL of collected media and a
capture/detector antibody cocktail were added to precoated wells and incubated for 1 h shaking
at 400 rpm. Following the immunocapture incubation period, the wells were washed and TMB
(TMB, 3,3t,5,5t-Tetramethylbenzidine) substrate was added, producing a color change based on
the amount of bound TNFα, which was then read at 450 nm. TNFα concentration was
determined using a standard curve. TNFα expression in TFV treated cell lysate was determined
using Western blot as described above. Each lane was loaded with 50 µg of protein; membranes
were probed using a rabbit-polyclonal HRP-linked antibody for TNFα diluted to 1:1000 in 5%
BSA/TBST (Abcam, Item No. ab66579). TNFα was normalized to protein and compared relative
to control.
Statistical Analysis
Values represent Mean ± SEM with 2–4 independent experiments conducted with 2–4
biological replicates. Differences between groups were determined with a one-way ANOVA
followed by a Holm–Sidak post-hoc test with p < 0.05 (SigmaStat, SSPS, Systat Software,
Chicago, IL, USA, Item Sigma Plot SPW11).
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Conclusions
HK-2 cells are a sensitive mode for examining TFV renal cytotoxicity. The
concentrations of TFV used in these studies are clinically relevant. Intracellular concentrations of
TFV can be higher than plasma levels as proximal tubule cells utilize active transport. TFV
reduced cell viability within 24 h. This is the first report to characterize TFV toxicity using HK-2
cells. Our results show that TFV causes mitochondrial damage resulting in diminished cellular
ATP levels and cleavage of caspase 3 and 9. Further studies are needed to explore the specific
cellular mechanism of mitochondrial toxicity and oxidative stress. The study also showed that
ascorbic acid, an antioxidant, could reduce TFV cytotoxicity.
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Abstract
Tenofovir (TFV) is an antiviral drug approved in the United States for treating Human
Immunodeficiency Virus (HIV) and Hepatitis B. TFV is administered orally as the prodrug
tenofovir disoproxil fumarate (TDF) which then is deesterified to the active drug TFV. TFV
induces nephrotoxicity characterized by decreased glomerular filtration rate (GFR), renal failure,
and Fanconi Syndrome. The mechanism of this toxicity remains largely unknown due to limited
experimental models. In a previously published study, we determined that TFV reduces cell
viability, causes oxidative stress, and induces apoptosis in the human renal proximal tubular cell
line (HK-2). This study further investigated the cellular mechanism of cytotoxicity using HK-2
cells. HK-2 cells were grown for 48 h followed by 24 to 72 h exposure to 0-28.8 μM TFV or
vehicle, phosphate buffered saline (PBS). A parallel study was run investigating the effects of
antioxidant pretreatment on TFV induced toxicity. HK-2 cells were treated with N-acetyl-Lcysteine (NAC), ascorbic acid, or resveratrol followed by 24 h exposure to 3 or 14.5 μM TFV, or
PBS. TFV reduced cell viability in 24-72 h as shown by MTT. Lactate dehydrogenase (LDH)
was released into the media following 24 h exposure to 14.5 and 28.8 μM TFV. TFV increased
the oxidative stress biomarker of protein carbonylation in the mitochondrial subcellular fraction
relative to control following TFV exposure. Manganese superoxide dismutase (MnSOD) and
cytochrome c were released into the cytosolic subcellular fraction relative to control following
TFV exposure. Mitochondrial function was assessed using Seahorse XFp assays; TFV reduced
basal and uncoupled cellular respiration when compared to vehicle at 24-72 h, but did not alter
spare respiratory capacity. Pretreatment with NAC, ascorbic acid, or resveratrol reduced TFV
toxicity in HK-2 cells. These studies suggest that TFV induces necrotic cell death at 24-48 h,
causes oxidative damage to the mitochondria leading to increased membrane permeability, and
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alters mitochondrial function. Damage from oxidative stress may be an important factor in the
mechanism of TFV induced cytotoxicity, as toxicity was prevented using an antioxidant
pretreatment.
Introduction
Tenofovir disoproxil fumarate (TDF) is an antiretroviral agent that is approved in the
United States to treat Human Immunodeficiency Virus (HIV) and chronic Hepatitis B (HBV).
Tenofovir (TFV) is a nucleotide analogue of adenosine 5’-monophosphate that competes for
incorporation into the growing viral strand during chain elongation and blocks reverse
transcriptase, leading to chain termination (Balzarini et al., 1993; Robbins et al., 1998). To
improve its oral bioavailability, it is administered as the prodrug TDF, which is deesterified
intracellularly to active TFV (Choi et al., 2008; Shaw et al., 1997). Its long half-life provides for
once a day dosing, which is beneficial for compliance (Barditch-Crovo et al., 2001; Deeks et al.,
1998; Durand-Gasselin et al., 2009). TFV is also effective in patients who have resistant HIV-1,
making it an essential drug in the treatment of HIV according to the World Health Organization
(Miller et al., 2001; Squires et al., 2003).
While TFV has many positive attributes, renal toxicity remains an adverse effect
associated with clinical use. TFV can induce increases in serum creatinine levels and higher
plasma vitamin D binding, decreases in glomerular filtration rate (GFR) and free calcitriol,
Fanconi Syndrome, and renal failure (Del Palacio et al., 2012; Hall et al., 2011; Havens et al.,
2013). Fanconi syndrome is a disorder of renal tubular function that results in excess excretion
of potassium, phosphate salts, protein, urate, and glucose. Clinical studies indicate that the
mitochondria of the proximal tubules are the target of TFV induced toxicity as shown by
enlarged and malformed mitochondria in electron microscopy cross sections (Cote et al., 2006;
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Hall et al., 2011; Herlitz et al., 2010; Woodward et al., 2009). Proximal tubular mitochondrial
toxicity has also been described in mice and rats treated with TFV as shown by disruptions in
mitochondrial cristae and a reduction in mtDNA levels (Kohler et al., 2009; Lebrecht et al.,
2009).
Though TFV induced renal toxicity has been documented, very little is known about the
mechanism; this knowledge gap may be due in part to limited experimental models. In vitro
studies have used primary renal proximal tubule cells treated for up to 22 days and in vivo mice
and rat models were treated with oral gavage for 5-8 weeks (Kohler et al., 2009; Lebrecht et al.,
2009; Vidal et al., 2006; Wang & Flint, 2013). The duration of these experiments can hamper
mechanistic studies, and the added stress of daily oral gavage can complicate mechanistic studies
using animal models. Cell lines with better responsiveness to TFV could circumvent these
issues.
In our previous study, our laboratory reported that Human Kidney-2 cells (HK-2) were a
suitable model to study TFV induced renal cytotoxicity. HK-2 cells retain similar activity and
biochemical properties to in vivo cells and are commonly used in renal mechanistic studies
(Gunness et al., 2010; Miyamoto et al., 2012; Paolicchi et al., 2003; Ryan et al., 1994). Using
clinically relevant concentrations, we determined that TFV causes oxidative stress, reduced
cellular ATP levels, and induced apoptosis within 72 h (Murphy, Stafford, Petrasovits, Boone, &
Valentovic, 2017). The purpose of this study was to further establish the mechanism of TFV
induced renal cytotoxicity as well as to begin preliminary tests on toxicity prevention.
In this manuscript, we demonstrate that TFV causes lactate dehydrogenase (LDH)
leakage and reduces mitochondrial function via oxidative stress and loss of membrane integrity.
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Additionally, our studies showed that TFV cytotoxicity may be prevented or mitigated using
antioxidant pretreatment.
Methods
Chemicals and Reagents
TFV was purchased from Cayman Chemicals (Item No. 13874, Ann Arbor, MI) and was
used for all studies. The cell treatment vehicle was phosphate buffered saline (Invitrogen,
Carlsbad, CA, Item No. 14175095). Resveratrol, N-acetyl-L-cysteine (NAC) and other
chemicals were purchased from Sigma Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburg,
PA). Antibodies and kits were purchased as indicated in the sections below.
Cell Lines and Tenofovir Treatment
Human immortalized epithelial HK-2 cells were purchased from the American Type
Culture Collection (ATCC) and were cultured according to ATCC guidelines. In brief, cells were
grown in a keratinocyte-free media with 50 µg/ml bovine pituitary extract and 5ng/ml
recombinant epithelial growth factor from Invitrogen (Carlsbad, CA, Item No. 17005-04) in a
warm humidified incubator with constant settings of 37oC and 5% CO2. HK-2 cells were plated
into six-well tissue culture plates (Corning, Sigma Aldrich Item No. CLS3516), 75 ml tissue
culture flasks (USA Scientific, Item No. CC7682-7506) or T75 tissue culture flasks (USA
Scientific, Item No. CC7682-4175) at a concentration of 750,000 cells/ml and allowed to grow
for 48 h. Media was replaced and cells were treated with a final concentration of 0, 14.5, or 28.8
uM TFV for 24, 48, or 72 h. The vehicle was an equal volume of phosphate buffered saline
(PBS). Following each treatment period, cells were collected with Trypsin-EDTA (0.25%)
(Invitrogen, Item No. 25200072) for sample analysis.
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Cell Viability
Cells were plated into 48-well tissue culture plates (39, 000 cells/ml) and allowed to grow
for 48 h followed by treatment with vehicle or TFV. Following the treatment period, cell
viability was assessed using the MTT assay (Humphrey et al., 2005). This assay relies on the
conversion of tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) to formazan by NAD(P)H-dependent oxidoreductases.
When cells lose membrane integrity as necrosis develops following exposure to a
toxicant, LDH is released from the cell into the extracellular space. This leakage can be used as
a quantification of cell death via necrosis. Western blot analysis was used to evaluate LDH
leakage from HK-2 cells into the media. Following the 24-48 h treatment period with vehicle or
TFV, cells were pelleted, rinsed with 500 µl PBS, and centrifuged. The pellet was then disrupted
with lysis buffer. Media samples were centrifuged at 2,000xg for ten min to remove any cell
debris. Protein content was measured, and each lane was loaded with 10 µg of protein.
Membranes were probed using a rabbit polyclonal antibody for LDH (Abcam, Item No.
ab47010; 1:500 dilution in 5% BSA/TBST). Results from three independent experiments were
analyzed with BioRad Chemidoc densitometry software (version 4.0.1).
Mitochondrial Isolation
Following collection with Trypsin-EDTA, mitochondria were isolated using a
Mitochondrial Isolation Kit for Cultured Cells (Thermo Scientific, Item No. 89874) and
differential centrifugation. Mitochondria were isolated according to the manufacturer’s
directions, with the exception of added protease inhibitor. Briefly, cells were centrifuged at
850xg for ten min and resuspended in 800 μL of Reagent A with added protease inhibitor.
Samples were vortexed for five sec at maximum speed and then incubated on ice for two min.
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Following addition of 10 μL of Reagent B, samples were vortexed for five sec at maximum
speed and incubated on ice for ten minutes, vortexing every minute. Next, 800 μL of Reagent C
with added protease inhibitor was added and the samples were centrifuged at 750xg for ten min.
The supernatant was transferred to new sample tubes and centrifuged at 12,000xg for 15 min at
4oC. The supernatant (cytosolic fraction) was transferred to a new tube and the pellet
(mitochondrial fraction) was resuspended in 75 μL cell lysis buffer.
Oxyblot and Western Blot
Western blot analysis was conducted to assess protein expression of manganese
superoxide dismutase (MnSOD), ATP Synthase, and cytochrome c in mitochondrial and
cytosolic subcellular fractions. Protein concentration in each sample was determined using the
Bradford protein assay (Bradford, 1976). A 40 μg aliquot of each sample was boiled for five min
to denature it. Proteins were then separated on a 12.5% polyacrylamide gel and transferred to a
nitrocellulose membrane (Bio-Rad, Item No. 1620097); successful transfer and protein loading
were verified using Memcode Reversible Protein Stain Kit (Pierce Biotechnology, Fisher
Scientific, Item No. PI-24580). Membranes were blocked using either a 5% w/v milk/TBST
solution (10mM Tris-HCl, 150mM NaCl, 0.1% Tween-20; pH 8.0) or a 3% Bovine Serum
Albumin (BSA)/PBST solution for one h. Membranes were next incubated with continual
shaking overnight at 4oC with a rabbit polyclonal antibody for MnSOD (Abcam, Item No.
ab13534, 1:500 dilution), ATP Synthase (1:1000 dilution) (Cell Signaling Technology, Item No.
9502) or cytochrome c (Cell Signaling, Item No. 4272, 1:1000 dilution). The membranes were
washed four times with TBST and goat anti-rabbit HRP-linked secondary antibodies (Santa Cruz
Biotechnology, Item No. sc-2030, 1:5000 dilution in 5% milk/TBST) and added for one h.
Membranes were washed again with TBST and then developed using Amersham ECL Western
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Blotting Detection Agent (GE Healthcare Life Sciences, Item No. RPN2232). A BioRad
chemic-doc system was used to capture the gel image and used for densitometry analysis. All
western analyses were conducted as three independent experiments. Western blot was also
conducted as described above using two mouse polyclonal antibodies, cytochrome c oxidase IV
(COX-IV, Abcam, Item No. ab14744) and cytochrome c oxidase subunit 1 (MtCO-1, Abcam,
Item No. 14705). COX-IV was diluted 1:1000 in 5% w/v milk/TBST and MtCO-1 was diluted
1:2000 in 3% w/v milk/TBST. Following washing with TBST, membranes were treated with a
goat anti-mouse HRP-linked secondary antibody for one h (Santa Cruz Biotechnology, Item No.
sc-2005). Membranes were washed and developed as described previously.
There are several markers of oxidative stress, including protein carbonylation, which can
produce an aldehyde or ketone side chain on cellular proteins. Protein carbonylation was
analyzed using the Oxyblot Protein Oxidation Detection Kit (EMD Millipore, Item No. S7150).
A 25 μg aliquot of sample was derivatized as previously described and protein loading was
verified using the MemCode Protein Stain (Terneus et al., 2007). Briefly, protein carbonyl
moieties on cellular proteins generated by oxidative stress are derivatized in the presence of 2,4dinitrophenylhydrazine (DNPH) to stable 2,4-dinitrophenylhydrazone groups; the primary
antibody (1:150 dilution in 1% BSA/PBST) recognizes these 2,4-dinitrophenylhydrazone groups
on proteins. Results from three independent experiments were analyzed with BioRad Chemidoc
densitometry software (version 4.0.1, Catalog No. 170-9690, BioRad, Hercules, CA, USA).
Seahorse XFp Assays
Seahorse XFp Assays allow measurement of basal Oxygen Consumption Rate (OCR) and
Extracellular Acidification Rate (ECAR), as well as following injection of compounds to identify
sources of mitochondrial impairment. Mitochondrial function was measured using Agilent Cell
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Phenotype, Mitochondrial Stress, and Glycolytic Stress Assays following optimization of cell
number per well.
Briefly, cells were cultured in XFp Culture Miniplates (25,000 cells/ml) (Agilent
Technologies, Item No. 103025-100) and allowed to grow for 48 h followed by treatment with
vehicle or TFV. Prior to the assay, cells were washed with assay media (Agilent Technologies,
Item No. 103334-100) supplemented with 1 mM pyruvate, 2 mM glutamine, and 0 mM glucose
and equilibrated in 180 μL pre-warmed assay media at 37oC with no CO2 for one h. In each
assay, three basal OCR/ECAR measurements were taken at seven minute intervals using the
Seahorse XFp instrument system. Following basal measurements, various probes were injected
and additional OCR and ECAR measurements were taken. Maximal respiration was stimulated
by the addition of Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) an uncoupler
of mitochondrial function. In the Cell Phenotype Assay, stressor mix was injected at
approximately minute 15 (50 μM FCCP/50 μM oligomycin) to uncouple the electron transport
chain (Agilent Technologies, Item No. 103275-100) and OCR and ECAR were measured in six
minute intervals. In the Mitochondrial Stress Test (Agilent Technologies, Item No. 103015100), injections of oligomycin (0.5 µM), FCCP (0.5 μM), and a mixture of Rotenone/Antimycin
A (0.5 μM) were added and OCR and ECAR were measured. Preliminary studies optimized the
FCCP concentration to 0.5 μM. In the Glycolysis Stress Test (Agilent Technologies, Item No.
103020-100), glucose (10 mM), oligomycin (1 µM), and 2-DG (50 mM) were injected and OCR
and ECAR were measured.
Following each assay, cells were washed with 200 μL PBS and lysed. Protein
concentration was assessed using the Bradford Assay as previously described (Bradford, 1976).
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Results were normalized to total protein concentration and analyzed using Wave Software
(Agilent Technologies, Wave for Desktop, Version 2.3.0.19).
Antioxidant Protection Studies
A separate series of experiments evaluated whether various antioxidants could provide
protection from TFV. HK-2 cells were allowed to grow for 48 h followed by a one h
pretreatment with resveratrol (5, 7.5, or 10 µM in DMSO), N-acetyl-L-cysteine (NAC, 0.5 or 1
mM in sterile water), or ascorbic acid (10 or 25 μM in sterile water) followed by a 24 h
incubation with 0, 3, or 14.5 μM TFV. Viability of cells was assessed using the MTT assay. All
media and MTT were removed from the cells prior to the addition of DMSO to prevent any
interaction of antioxidants with formazan.
Statistical Analysis
Data are presented as Mean ± SEM with 2–4 independent experiments with 2–4
biological replicates. Differences between groups were determined with a one-way ANOVA
followed by a Holm–Sidak post-hoc test with p < 0.05 (SigmaStat, SSPS).
Results
TFV Effects on Cell Viability
TFV was cytotoxic to HK-2 cells as cell viability was diminished within 24 h when
compared to vehicle based on the MTT assay. TFV reduced cell viability at 24 h (p<0.001) at
both concentrations tested (Figure 12). Cell Viability continued to be diminished at 48 and 72 h,
with 28.8 μM TFV showing additional decline in viability (p<0.05).
In our previous study, we determined that TFV initiates apoptosis at 72 h, but not at 24 or
48 h. Western blot was run on tissue and media samples treated with TFV to determine if
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multiple mechanisms of toxicity occur. LDH leakage from tissue into media was increased at 24
and 48 h (p<0.01) but not at 72 h (Figure 13). This leakage is indicative of necrosis.

Figure 12. TFV cytotoxic effects on HK-2 cell viability using MTT. Tenofovir decreased cell
viability at 24 (A), 48 (B), and 72 h (C). Different superscript letters (a-c) indicate difference
between treatment groups (p<0.05) at the designated time period. D) Depicts cell viability
following 72 h exposure to tenofovir in experiments where mitochondria were isolated to ensure
treatment success. Each bar represents Mean ± SEM for four independent experiments run with
three biological replicates.
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Figure 13. LDH expression in HK-2 cell lysate and media following tenofovir (TFV)
exposure. LDH release into media (M) and HK-2 cell lysate (T) expressed as percent of control
following 24 (A) and 48 h (B) exposure to TFV. LDH release into the media was increased
(p<0.01) relative to control at all concentrations and time points. Different superscripts (a-c)
indicate differences between treatment groups at designated time periods. C) and D) depict
densitometry and representative blots for 10 µg protein loading of cell lysates and media samples
for 24 (C) and 48 h (D) TFV exposure visualized with Memcode Reversible Protein Staining.
Each bar represents Mean ± SEM for two independent experiments run with three biological
replicates.

TFV Effects on Mitochondrial Stress and Membrane Integrity
Mitochondrial oxidative stress was induced by 28.8 μM TFV relative to control at 72 h
(p<0.05) as shown by Oxyblot analysis (Figure 14). Protein carbonylation was not increased in
the cytosolic fraction relative to control. A 72 h exposure to TFV also caused leakage of
MnSOD from mitochondria to the cytosol relative to control (p<0.001, Figure 14). Loss of this
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enzyme within the mitochondrial antioxidant system may further contribute to the observed
oxidative damage.
TFV alters mitochondrial membrane integrity as shown by MnSOD leakage (Figure 14).
Additional studies on mitochondrial proteins were conducted to assess the extent of
mitochondrial membrane damage. TFV caused leakage of cytochrome c from the mitochondria
to the cytosol relative to control (p<0.001) as shown by western blot (Figure 15). However, TFV
did not induce leakage of ATP Synthase into the cytosol (Figure 15). The observed difference
may be due to localization of proteins within the mitochondria. ATP synthase is located in the
inner mitochondrial membrane while cytochrome c is located in the intermitochondrial space.
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Figure 14. Tenofovir (TFV) treatment of HK-2 cells for 72 h increases protein
carbonylation and induces leakage of manganese superoxide dismutase (MnSOD). A)
Protein carbonylation in HK-2 mitochondrial and cytosolic fractions following 72 h exposure to
28.8 µM TFV. B) MnSOD expression in mitochondrial and cytosolic fractions following 72 h
exposure to 28.8 μM TFV. C) and D) depict densitometry and representative blots for 25 µg (C)
and 40 µg (D) protein loading of cytosolic and mitochondrial fractions of cell lysates for 72 h
TFV exposure visualized with Memcode Reversible Protein Staining. Asterisks represent
differences between groups (*p<0.05, ***p<0.001). Each bar represents Mean ± SEM for three
independent experiments run with three biological replicates.
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Figure 15. Tenofovir (TFV) alters mitochondrial membrane integrity. A) Expression of
cytochrome c in mitochondrial and cytosolic fractions of cell lysate following 72 h exposure to
28.8 μM TFV. B) Expression of ATP Synthase in mitochondrial and cytosolic fractions of cell
lysate following 72 h exposure to 28.8 µM TFV. C) and D) depict densitometry and
representative blots for 40 µg protein loading of cytosolic and mitochondrial fractions of cell
lysates for 72 h TFV exposure visualized with Memcode Reversible Protein Staining. Asterisks
represent differences between groups (***p<0.001). Each bar represents Mean ± SEM for three
independent experiments run with three biological replicates.

TFV Effects on Mitochondrial DNA
There are conflicting reports on whether TFV inhibits mitochondrial DNA replication, as
some studies have reported TFV is a weak inhibitor of DNA Polymerase γ (Pol γ). We assessed
this effect in our cell model via expression of cytochrome c oxidase subunits following 72 h
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exposure to TFV. TFV did not alter the expression or localization of the nuclear-encoded
subunit, COX-IV, or the mitochondrial-encoded subunit, MtCO-1 (Figure 16). These data
indicate that 28.8 μM TFV does not affect mitochondrial DNA replication under the
experimental conditions of 72 h exposure.

Figure 16. TFV does not alter expression or localization of subunits of cytochrome c
oxidase. A) Expression of nuclear-encoded subunit, COX-IV, in mitochondrial and cytosolic
fractions of cell lysate following 72 h exposure to 28.8 μM TFV. B) Expression of
mitochondrial-encoded subunit, MtCO-1, in mitochondrial and cytosolic fractions of cell lysate
following 72 h exposure to 28.8 μM TFV. C) and D) depict densitometry and representative
blots for 40 μg protein loading of cytosolic and mitochondrial fractions of cell lysates for 72 h
TFV exposure visualized with Memcode Reversible Protein Staining. Each bar represents Mean
± SEM for three independent experiments run with three biological replicates.
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TFV Effects on Mitochondrial Function
Mitochondrial function was assessed using a Seahorse XFp instrument. In the cell
phenotype assay, basal oxygen consumption rate (OCR) was reduced by 27% and basal
extracellular acidification rate (ECAR) was reduced by 16% at 72 h exposure to TFV when
compared to vehicle (p<0.05) (Figure 19); however, basal OCR and ECAR were similar to
control at 24 and 48 h TFV exposure (Figure 17, Figure 18). The addition of FCCP and
oligomycin uncouples the electron transport chain and inhibits ATP synthase, respectively,
causing a compensatory increase in glycolysis and OCR to try to restore membrane potential and
meet energy demands. At 24-72 h exposure to TFV, stressed OCR were reduced relative to
control at all concentrations tested (p<0.05, Figure 17, Figure 18, Figure 19). Stressed ECAR
was reduced at 72 h exposure (p<0.05, Figure 19) but not at 24 or 48 h exposure (Figure 17,
Figure 18).
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Figure 17. Cell Phenotype Assay, oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) following 24 h TFV exposure. A) Basal vs. stressed OCR
following 24 h exposure to TFV. B) Time course graph of OCR in the cell phenotype assay
following 24 h TFV exposure. C) Basal vs. stressed ECAR following 24 h TFV exposure.
Different superscripts (a-d) represent differences between groups (p<0.05). D) Time course
graph of ECAR in the cell phenotype assay following 24 h TFV exposure. Bar graphs are
presented as Mean ± SEM for four independent experiments run with two biological replicates.
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Figure 18. Cell Phenotype Assay, oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) following 48 h TFV exposure. A) Basal vs. stressed OCR
following 48 h exposure to TFV. B) Time course graph of OCR in the cell phenotype assay
following 24 h TFV exposure. C) Basal vs. stressed ECAR following 48 h TFV exposure.
Different superscripts (a-d) represent differences between groups (p<0.05). D) Time course
graph of ECAR in the cell phenotype assay following 48 h TFV exposure. Bar graphs express
data as Mean ± SEM for four independent experiments run with two biological replicates.
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Figure 19. Cell Phenotype Assay, oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) following 72 h TFV exposure. A) Basal vs. stressed OCR
following 72 h exposure to TFV. B) Time course graph of OCR in the cell phenotype assay
following 72 h TFV exposure. C) Basal vs. stressed ECAR following 24 h TFV exposure.
Different superscripts (a-d) represent differences between groups (p<0.05). D) Time course
graph of ECAR in the cell phenotype assay following 72 h TFV exposure. Bar graph values
expressed as Mean ± SEM for four independent experiments run with two biological replicates.

A mitochondrial stress test was run following 24-72 h TFV exposure to further explore
the observed reduction in stressed OCR in the cell phenotype assay. In this assay, probes are
serially injected to reveal key parameters of mitochondrial function. Oligomycin inhibits ATP
synthase and the resulting decrease in OCR correlates to mitochondrial respiration linked to ATP
production. FCCP is an uncoupling agent that increases oxygen consumption to maximal levels,
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which can be used to calculate spare respiratory capacity. The final injection of antimycin
A/rotenone inhibits complex I and III, allowing for calculation of non-mitochondrial respiration.
Exposure to 14.5 and 28.8 μM TFV caused a decrease in basal (p<0.001) and maximal
(p<0.05) OCR at 72 h exposure, but not at 24-48 h (Figure 20, Figure 21, Figure 22). ATP
production was also decreased at 72 h following exposure to 28.8uM TFV (p<0.05, Figure 22)
but not at 24-48 h (Figure 20, Figure 21). Spare respiratory capacity was not affected at any time
point or concentration tested (Figure 20, Figure 21, Figure 22).

Figure 20. Mitochondrial Stress Test, effects of TFV on ATP production and mitochondrial
respiratory capacity. Basal (A) and Maximal (B) OCR following 24 h exposure to TFV. C)
Spare respiratory capacity following 24 h TFV exposure. D) Time course graph of OCR in the
mitochondrial stress test following 24 h TFV exposure. Bar graph values represent Mean ±
SEM for four independent experiments run with two biological replicates.
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Figure 21. Mitochondrial Stress Test, effects of TFV on ATP production and mitochondrial
respiratory capacity. Basal (A) and Maximal (B) OCR following 48 h exposure to TFV. C)
Spare respiratory capacity following 48 h TFV exposure. D) Time course graph of OCR in the
mitochondrial stress test following 48 h TFV exposure. Bar graph values are presented as Mean
± SEM for four independent experiments run with two biological replicates.
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Figure 22. Mitochondrial Stress Test, effects of TFV on ATP production and mitochondrial
respiratory capacity. Basal (A) and Maximal (B) OCR following 72 h exposure to TFV. C)
Spare respiratory capacity following 72 h TFV exposure. Asterisks indicate differences between
groups (*p<0.05, **p<0.01). D) Time course graph of OCR in the mitochondrial stress test
following 72 h TFV exposure. Bar graph values are presented as Mean ± SEM for four
independent experiments run with two biological replicates.

Based on the ECAR results in the cell phenotype assay, glycolytic stress tests were run at
72 h TFV exposure to further elucidate the effect of TFV on glycolysis. Cells are saturated with
glucose, and basal ECAR was assessed. Oligomycin is then injected to inhibit ATP synthase and
drive glycolysis to maximal capacity. Finally, 2-DG, a glucose analog, is injected to inhibit the
first enzyme in the glycolytic pathway, hexokinase; the resultant decrease in ECAR ensures that
the ECAR produced in the experiment is due to glycolysis. TFV exposure had no effect on any
measured glycolytic parameters (Figure 23).
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Figure 23. Glycolytic Stress Test, effects of TFV on glycolytic capacity and reserve. Basal
(A) and Maximal (B) ECAR following 72 h exposure to TFV. C) Spare glycolytic capacity
following 72 h TFV exposure. D) Glycolytic reserve following 72 h exposure to TFV. E)
Time course graph of OCR in the glycolytic stress test following 72 h TFV exposure. Bar graph
values are presented as Mean ± SEM for four independent experiments run with two biological
replicates.

Antioxidant Protection of TFV Cytotoxicity
Our previous study showed that oxidative stress was increased by TFV resulting in
increased protein carbonylation and 4-hydroxynonenol (4-HNE) adduct formation, suggesting
that a rise in reactive oxygen species occurs with TFV cytotoxicity. Pretreatment with ascorbic
acid, resveratrol, and N-acetyl-L-cysteine (NAC) reduced TFV toxicity in HK-2 cells; cell
viability was higher in cells exposed to TFV in the presence of antioxidants compared to TFV
alone (Figure 24, Figure 25, and Figure 26). While 0.5 mM NAC did protect from TFV
cytotoxicity, it did not provide enough protection to return viability to the same level as control
(Figure 24). Additionally, 25 μM ascorbic acid did protect from 14.5 μM TFV cytotoxicity, but
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it did not provide enough protection to return viability to the same level as control (Figure 25).
These findings suggest that use of an antioxidant pretreatment can reduce TFV cytotoxicity in
HK-2 cells.

Figure 24. Effects of N-acetyl-L-cysteine (NAC) pretreatment on TFV cytotoxicity. Nacetyl-L-cysteine (NAC) protected HK-2 cells from tenofovir cytotoxicity as assessed by MTT
viability. Cells were treated with 0 (−), 0.5 mM (+), or 1 mM (+) NAC followed by a 24 h
exposure to 0 (−), 3 μM (+) or 14.5 µM (+) TFV. Different superscript letters (a-d) indicate
statistical difference from all other groups (p<0.05). Values represent Mean ± SEM for three
independent experiments run with three biological replicates.
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Figure 25. Effects of ascorbic acid (Asc) pretreatment on TFV cytotoxicity. Asc protected
HK-2 cells from tenofovir cytotoxicity as assessed by MTT viability. Cells were treated with 0
(−), 10 μM (+), or 25 μM (+) Asc followed by a 24 h exposure to 0 (−), 3 μM (+) or 14.5 µM (+)
TFV. Different superscript letters (a-c) indicate statistical difference from all other groups
(p<0.05). Values represent Mean ± SEM for three independent experiments completed after
publication of the previous study run with three biological replicates.
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Figure 26. Effects of resveratrol (Res) pretreatment on TFV cytotoxicity. Res protected HK2 cells from tenofovir cytotoxicity as assessed by MTT viability. Cells were treated with 0 (−), 5
μM (+), 7.5 μM (+), or 10 μM (+) Asc followed by a 24 h exposure to 0 (−), 3 μM (+) or 14.5
µM (+) TFV. Different superscript letters (a-b) indicate statistical difference from all other
groups (p<0.05). Values represent Mean ± SEM for three independent experiments run with
three biological replicates.

Discussion
TFV is a very effective antiviral nucleotide reverse transcriptase inhibitor prescribed
worldwide in the treatment of HIV and Hepatitis B. Unfortunately, patients treated with TFV
have an increased incidence of renal impairment (Fux et al., 2007; Verhelst et al., 2002). Renal
TFV toxicity in humans is characterized by Fanconi Syndrome and development of irreversible
impaired renal function depending on the dose. There is a positive correlation between increased
TFV plasma concentration, renal toxicity and the duration that patients were treated with TFV
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(Ezinga et al., 2014; Quesada et al., 2015). Examination of the mechanism of TFV induced renal
toxicity is clinically relevant because HIV treatment is chronic. Understanding the mechanism of
TFV nephrotoxicity is essential for the development of methods to mitigate TFV renal
impairment.
Our current studies further probed TFV renal cytotoxicity in HK-2 cells, which are an
effective model for examining TFV nephrotoxicity. In a previously published paper, we showed
that treatment with clinically relevant concentrations of TFV reduced cell viability in HK-2 cells
within 24 h. We also showed that TFV increased protein carbonylation and 4-HNE adduct
formation in whole cell lysate at 72 h exposure and induced apoptosis via activation of caspase 3
and 9. There is also marked reduction in intracellular ATP at 72 h, but not 24 or 48 h TFV
exposure (Murphy et al., 2017). These data provide insight into the mechanism of TFV induced
cytotoxicity, but also leave many questions.
Our previous study (Murphy et al., 2017) supported the hypothesis that mitochondrial
damage and oxidative stress play a role in TFV induced cytotoxicity; the current study further
probed this mechanism. While TFV induced apoptosis at 72 h exposure as shown by caspase 3
and 9 cleavage, activation of these proteins was not observed at lower time points. Additionally,
intracellular ATP was not affected until 72 h exposure, indicating that multiple mechanisms of
toxicity may be involved. When cells undergo necrosis, organelles swell and break down,
leading to disruption of plasma membrane integrity (Challa & Chan, 2010; Moquin & Chan,
2010; Schweichel & Merker, 1973). This loss in membrane integrity leads to the release of
intracellular contents. LDH is a stable enzyme that is expressed in every cell type; it is
commonly used as a marker of necrosis (Burd & Usategui-Gomez, 1973; Chan, Moriwaki, & De
Rosa, 2013). Our study showed an increase in LDH release from HK-2 cells into the media
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following 24 and 48 h exposure to TFV (Figure 13), indicating that TFV induces necrosis in HK2 cells within 24 h exposure. These findings are in line with clinical data of patients with TDF
induced renal injury, which show marked tubular necrosis (Herlitz et al., 2010).
The results of our previous study also indicated that the mitochondria are the target of
TFV renal cytotoxicity. Clinical studies found that the mitochondria of the proximal tubules are
the target of TFV induced toxicity as shown by enlarged and malformed mitochondria in electron
microscopy cross sections from patients taking 300 mg TDF for approximately seven years (Cote
et al., 2006; Hall et al., 2011; Herlitz et al., 2010; Woodward et al., 2009). Cytochrome c
excretion into urine is observed clinically in HIV patients who have developed TFV induced
nephropathies (Maggi et al., 2012). Proximal tubular mitochondrial toxicity has also been
described in mice and rats treated with TFV as shown by disruptions in mitochondrial cristae and
a reduction in mtDNA levels (Kohler et al., 2009; Lebrecht et al., 2009). The results of our
current study are in accordance with these findings. TFV increased oxidative damage in the
mitochondrial fraction of HK-2 cells, but not the cytosolic subcellular fraction (Figure 14).
Additionally, there is a loss in mitochondrial membrane integrity, as indicated by the presence of
cytochrome c and MnSOD in the cytosolic subcellular fraction following 72 h TFV exposure
(Figure 14 and 15). Release of cytochrome c to the cytosol induces apoptosis via binding to
Apoptotic protease activating factor 1 (Apaf-1) to form an apoptotic complex that activates
caspase 9 (Jiang & Wang, 2000; Liu, Kim, Yang, Jemmerson, & Wang, 1996).
Cytochrome c is a key component of the electron transport chain; cytochrome c
mitochondrial leakage into the cytosol may contribute to the loss of cellular ATP production
observed in our previous study. Interestingly, analysis of ATP synthase expression showed no
leakage into the cytosolic fraction or alteration in expression (Figure 15); ATP synthase is a
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membrane bound protein in the inner mitochondrial membrane and membrane breakdown may
not be severe enough to induce release of ATP synthase. It is unlikely that loss of ATP synthase
from the mitochondrial membrane contributes to the observed reduction in cellular ATP
following TFV exposure.
MnSOD is a nuclearly encoded mitochondrial antioxidant enzyme that is essential in
maintaining the balance of generation and detoxification of reactive oxygen species (ROS).
MnSOD functions mainly via detoxifying superoxide free radicals that are generated during
mitochondrial respiration. Oxidative stress occurs when there is an imbalance between the
generation and detoxification of ROS and reactive nitrogen species (RNS)(Fridovich, 1995).
The role of MnSOD in toxicity development in HIV patients has not been extensively studied.
However, one study has shown that Blood Urea Nitrogen (BUN) is elevated in wild type mice
treated with 50 mg/kg TDF but not in transgenic mice that overexpress MnSOD (Glover et al.,
2014). Our study shows that following 72 h exposure with 28.8 μM TFV, MnSOD leakage into
the cytosol increased 1.5-fold (Figure 14). This data indicates a loss in mitochondrial membrane
integrity following TFV exposure and may indicate a decreased ability to respond to oxidative
stress. Whether MnSOD leakage contributes to the observed oxidative damage is not yet clear as
there was no change in mitochondrial expression following TFV treatment. Additional study
needs to be conducted to determine more fully what role MnSOD plays in the development of
TFV renal cytotoxicity.
TFV has been shown to be a weak inhibitor of Pol γ, but effects on mitochondrial DNA
(mtDNA) show conflicting results, possibly due to variation between cell types. In a clinical
study, mtDNA was increased 1.4 fold in peripheral blood mononuclear cells (PBMCs) in HIV-1
infected patients taking 300mg TDF daily for 96 weeks (Curran et al., 2012). In a different study
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using an HIV transgenic mouse model, mtDNA was elevated following five weeks of daily TDF
treatment. However, further investigation into this study detected diminished mtDNA by TDF
compared to the vehicle group when laser capture microscopy was used to microdissect proximal
tubules of HIV-1 transgenic mice (Kohler et al., 2009). Conversely, exposing human primary
renal proximal tubule cells to 2 and 200 uM TFV for 19 days showed no change in mtDNA
compared to control (Wang & Flint, 2013). However, this same study reported TFV decreased
mtDNA in primary human adipocytes cultured for 19 days in the presence of 2 and 200 uM TDF.
No change in mtDNA was also reported when human renal proximal tubular epithelial cells were
incubated for 22 days with 30 uM TFV(Vidal et al., 2006).
The results of our study indicate that TFV does not alter mitochondrial DNA (Figure 5).
While we did not measure mtDNA directly, we assessed expression of both nuclear and
mitochondrial-encoded subunits of cytochrome c oxidase. TFV did not alter the expression or
localization of the nuclear-encoded subunit, COX-IV, or the mitochondrial-encoded subunit,
MtCO-1 (Figure 16). While it is possible that mtDNA is affected and there is a compensatory
increase in translation or a lower rate of enzyme turnover, our results are similar to another study
that assessed both mtDNA and cytochrome c oxidase expression following TFV exposure.
Rhesus monkeys, rats, and woodchucks were treated with varying doses of TDF for 56, 28, and
90 days respectively. Following the treatment period, cytochrome c oxidase and mtDNA levels
were unaltered in all models and treatment groups (Biesecker et al., 2003).
This is the first study to conduct functional studies to determine the effect of TFV on the
mitochondria. Using Seahorse XfP technology, we show that TFV alters mitochondrial function.
At 24 and 48 h TFV exposure, maximal OCR is lower relative to control but basal OCR is
unaffected (Figure 17, Figure 18). ECAR is not affected at either time point. However, at 72 h
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TFV exposure, basal OCR and ECAR, and maximal OCR and ECAR are lower relative to
control. Upon further investigation in the mitochondrial stress test, 72 h TFV exposure results in
lower ATP production, but does not affect spare capacity. This decline in ATP production is not
observed in lower time points, which is consistent with our previous study results.
The results of our study suggest TFV induces mitochondrial changes similar to other
mitochondrial toxicants. One study using hepatocellular carcinoma cells to evaluate 27
compounds found that Seahorse technology can be helpful in mitochondrial mechanistic studies.
Compounds such as rotenone, a known complex I inhibitor, show a decrease in OCR and spare
capacity, but an increase in ECAR. ATP synthase inhibitors such as oligomycin, show a
decrease in OCR with no effect on reserve capacity, while uncouplers such as 2,4-dinitrophenol
increase OCR and ECAR with no effect on reserve capacity (Eakins et al., 2016). These
extracellular flux assays were able to correctly predict the mechanisms of mitochondrial toxicity
in 76% percent of known test compounds used. As TFV reduces OCR but does not alter spare
capacity, it is possible that TFV inhibits ATP synthase activity; additional study needs to be done
to determine the direct inhibitory effects of TFV. Our studies indicated ATP synthase expression
was not diminished by TFV.
Eakins and associates (2016) further determined that known glycolytic inhibitors such as
clotrimazole induce reduced OCR and reserve capacity but no effect on ECAR levels. The
results of our glycolytic stress test show no effect on ECAR at 72 h exposure, but there is
reduced OCR (Figure 22); based on results of published glycolytic inhibitors, it is possible that
TFV alters glycolysis in some way. It remains unknown if the cause of decreased OCR and
ECAR following TFV exposure is due to loss of mitochondrial membrane integrity, direct
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enzyme inhibition, fewer functional mitochondria, or a combination of several factors. Further
studies need to probe the mechanism of mitochondrial toxicity.
Resveratrol and ascorbic acid are widely known as antioxidants and have been shown to
prevent renal toxicity of a number of chemotherapeutic agents that induce oxidative stress in
vitro and in vivo rodent models, including cisplatin and cadmium (Do Amaral et al., 2008; Fu,
Zhao, Peng, Wu, & Zhang, 2017; Koyuturk, Yanardag, Bolkent, & Tunali, 2007; Maliakel,
Kagiya, & Nair, 2008; Valentovic et al., 2014). N-acetyl-L-cysteine (NAC) is the precursor to
glutathione (GSH), an important cellular antioxidant. NAC is most notably used to treat
acetaminophen overdose by providing cysteine for glutathione synthesis to mitigate hepatic
toxicity, but has been shown to protect hepatocytes from oxidative damage induced by cadmium
and mercury in rats (Joshi, Mittal, Shukla, Srivastav, & Srivastav, 2014; Wang, Zhu, Liu, & Liu,
2014).
Our study shows that an hour pretreatment with resveratrol, NAC, or ascorbic acid
protects HK-2 cell viability when exposed for 24 h to 3 or 14.5 μM TFV (Figure 17). It should
be noted that high concentrations of NAC (0.5-1 mM) were required to induce a protective
effect; resveratrol may be the best choice in prevention of TFV induced cytotoxicity as it
required the lowest concentration to induce a protective effect (5 μM). It is unclear by what
mechanism antioxidants protect against TFV toxicity. Our previous studies did not show markers
of oxidative damage (protein carbonylation and 4-HNE adduct formation) until 72 h exposure,
but protection was observed in our current study within 24 h TFV exposure. Additional study
needs to be done to determine the role of reactive oxygen and nitrogen species at lower time
points as well as to elucidate the mechanism of antioxidant protection.
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Conclusion
This study provides additional insight into the mechanism of TFV induced renal
cytotoxicity. TFV induces necrosis within 24 h as shown by LDH release from HK-2 cells.
Oxidative stress is increased in mitochondria, and there is a loss of mitochondrial membrane
integrity, resulting in the release of MnSOD and cytochrome c into the cytosol. Cytochrome c
release further validates that TFV induces apoptosis at 72 h exposure. Mitochondrial function is
also altered, as shown by changes in OCR and ECAR in Seahorse XFp Assays. The role of
MnSOD in TFV induced cytotoxicity remains unclear. However, antioxidant pretreatment
attenuates TFV induced cytotoxicity, but the mechanism by which this occurs is unknown at this
time. Additional studies need to be conducted to determine to what degree TFV modulates
mitochondrial function and the mitochondrial antioxidant system, as well as investigate the
mechanism by which antioxidants protect against TFV induced oxidative damage.
Acknowledgments
This work was supported by NIH Grant P20GM103434 to the West Virginia IDeA
Network for Biomedical Research Excellence. Rachel A. Murphy was supported by a graduate
fellowship from the West Virginia NASA Space Grant Consortium.

83

CHAPTER 5
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS
At the end of my dissertation research, this project remains as exciting and fascinating as
it was when I came across it in my first year communications class. TDF is one of the most
widely prescribed drugs to treat HIV and it is effective in patients who have resistant HIV-1. As
resistance to HAART can be acquired and transmitted, medications with low resistance profiles
are key in successful treatment of HIV. This low resistance profile makes the renal toxicity
associated with TFV use particularly relevant. The goal of my work was to determine the
mechanism of TFV induced nephrotoxicity and to investigate potential methods to mitigate or
prevent said toxicity. My work provides insight into this mechanism as well as evidence that
antioxidant pretreatment mitigates this toxicity; this evidence warrants further study and has
potential clinical implications.
HK-2 Cells are a Suitable Model to Study TFV Cytotoxicity
One of the primary reasons that there is a knowledge gap regarding the mechanism of
TFV toxicity is a lack of suitable experimental models; mechanistic studies require a model that
is consistent with what occurs in humans. The selection of suitable models to study TFV
cytotoxicity has been problematic to date. For example, most in vivo models require subchronic
treatment of animals. TFV toxicity in rodents such as rats has required eight weeks of daily
treatment in order to develop nephrotoxicity (Lebrecht et al., 2009). In this study, rats treated for
eight weeks showed declined renal function and proximal tubular damage along with enlarged
mitochondria. Another study showed that treatment for five weeks with TFV induced oxidative
stress in Wistar rats. However, they were dosed with very high concentrations of TFV (Abraham
et al., 2013).
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An in vitro model was first reported by Wang and Flint that developed TFV cytotoxicity
using primary human kidney cells (Wang & Flint, 2013). Primary human kidney cells required
culturing for 19 days with 200 μM TFV to induce cytotoxicity, which was much longer and at
concentrations higher than pharmacological levels. The need for higher concentrations of TFV to
induce toxicity in primary proximal tubule cell lines may be due to differences in OAT1 and
OAT3 expression. Endogenous expression of OAT1 and OAT3 in primary human proximal
tubule cells has been shown to vary greatly from sample to sample (Lash et al., 2006) and TFVinduced cytotoxicity is dependent on OAT1 and OAT3 expression (Kohler et al., 2011; Nieskens
et al., 2016). Other cell types such as HEK293 cells have been used to study tenofovir
cytotoxicity, but appear less sensitive than our HK-2 model. One study showed that TFVinduced cytotoxicity within 48 h in HEK293 cells transfected with OAT1; however, the IC50 was
reported to be 316 μM (Zhang et al., 2015).
Our HK-2 cell model is more sensitive than human primary proximal tubule cells and
HEK293 cells as we have shown induction of cytotoxicity in 24 h compared to 22 days and at a
concentration almost ten times lower than previously reported for human primary proximal
tubular epithelial cells and almost 12 times lower than previously reported for HEK293 cells
(Vidal et al., 2006; Zhang et al., 2015). In addition to inducing cytotoxicity at 24 h, our HK-2
cell model has an IC50 of 9.2 μM TFV at 48 h, and an IC50 of 2.77 μM TFV at 72 h compared to
an IC50 at 48 h of 316uM (Zhang et al., 2015).
In our study, cell viability was diminished in HK-2 cells with TFV concentrations
ranging from 1.5 to 28.8 μM. These concentrations are clinically relevant as plasma TFV
concentrations have been reported to be 2.2 μM in HIV-1 infected patients (Barditch-Crovo et
al., 2001; Zhang et al., 2015). As described in Chapter 1, TFV plasma concentrations are higher
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in HIV-1 patients with existing renal insufficiency and patients with renal insufficiency also
experience a longer duration of TFV exposure, as shown by a 15-fold increase in AUC0–24 h
(Custodio et al., 2016; Ezinga et al., 2014; Sentenac et al., 2003). Therefore, HK-2 cells provide
a model that can be used to examine the mechanism of toxicity without the compounding
physiological parameters influencing the response of the kidney to a toxicant. Our studies further
showed that HK-2 cells can differentiate the toxicity of different antiviral agents as abacavir, an
agent that is considered less toxic to the kidney which was not toxic in our system (Figure 4D,
Chapter 2).
TFV Causes Oxidative Stress and Alters Mitochondrial Integrity in HK-2 Cells
In our study, we first probed whole cell lysate for markers of oxidative damage, protein
carbonylation, and 4-HNE adduct formation. Oxidative damage occurs following periods of
oxidative stress, an imbalance between the generation and detoxification of ROS and reactive
nitrogen species (RNS) (Fridovich, 1995). The HK-2 cells were more sensitive to TFV and
displayed increased oxidative stress at clinically relevant concentrations as compared to
previously examined models. A five week treatment of rats with 12 times higher dose than what
is clinically used reported a 25% increase in renal protein carbonylation (Abraham et al., 2013);
the HK-2 cells demonstrated a much greater increase in protein carbonylation within a shorter
time period than reported in vivo treatment of rats (Figure 7, Chapter 2). Additionally, we saw a
large increase in 4-HNE adduct formation at 72 h exposure (Figure 8, Chapter 2), indicating that
TFV induced oxidative stress leads to lipid peroxidation.
We further investigated oxidative damage following TFV exposure in subcellular
fractions. Clinical studies show that the mitochondria of the proximal tubules are the target of
TFV induced toxicity as shown by enlarged and malformed mitochondria in electron microscopy
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cross sections from patients taking 300 mg TDF for approximately seven years (Cote et al.,
2006; Hall et al., 2011; Herlitz et al., 2010; Woodward et al., 2009). Cytochrome c excretion
into urine is observed clinically in HIV patients who have developed TFV induced nephropathies
(Maggi et al., 2012). Proximal tubular mitochondrial toxicity has also been described in mice
and rats treated with TFV as shown by disruptions in mitochondrial cristae and a reduction in
mtDNA levels (Kohler et al., 2009; Lebrecht et al., 2009). The results of our current study are in
accordance with these findings. TFV increased oxidative damage in the mitochondrial fraction of
HK-2 cells, but not the cytosolic subcellular fraction (Figure 14, Chapter 3).
Additionally, there is a loss in mitochondrial membrane integrity, as indicated by the
presence of cytochrome c and MnSOD in the cytosolic subcellular fraction following 72 h TFV
exposure (Figure 14 and 15, Chapter 3). This loss in membrane integrity may be due to the lipid
peroxidation indicated by 4-HNE adduct formation. Interestingly, analysis of ATP synthase
expression showed no leakage into the cytosolic fraction or alteration in expression (Figure 15,
Chapter 3); ATP synthase is a membrane bound protein in the inner mitochondrial membrane
and membrane breakdown may not be severe enough to induce release of ATP synthase.
MnSOD is a nuclearly encoded mitochondrial antioxidant enzyme that is essential in
maintaining the balance of generation and detoxification of reactive oxygen species (ROS).
MnSOD functions mainly via detoxifying superoxide free radicals that are generated during
mitochondrial respiration. The role of MnSOD in toxicity development in HIV patients has not
been extensively studied. However, one study has shown that Blood Urea Nitrogen (BUN) is
elevated in wild type mice treated with 50 mg/kg TDF but not in transgenic mice that
overexpress MnSOD (Glover et al., 2014). Our study shows that following 72 h exposure with
28.8 μM TFV, MnSOD leakage into the cytosol increased 1.5-fold (Figure 3, Chapter 2). This
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data indicates a loss in mitochondrial membrane integrity following TFV exposure and may
indicate a decreased ability to respond to oxidative stress. Whether MnSOD leakage contributes
to the observed oxidative damage is not yet clear as there was no change in mitochondrial
expression following TFV treatment.
TNFα is a proinflammaotry cytokine which is expressed in proximal tubular epithelial
cells. TNFα can be secreted from cells to induce an inflammatory response as a protective
mechanism during initial exposure to toxicants (Gu et al., 2016). TNFα expression can induce
reactive oxygen species generation via mitochondria and through activation of NADPH oxidase
(Morgan, 2010). Mitochondrial damage and generation of reactive oxygen species can stimulate
the release of various cytokines including TNFα (Mittal et al., 2014). These changes in TNFα
expression and secretion can modulate various parts of the cellular antioxidant system and
directly increase the production of mitochondrial reactive oxygen species through damage to the
electron transport chain (Mittal et al., 2014). In experiments involving exposing HK-2 cells to
toxicants and/or ischemic injury, TNFα levels rose along with many other markers of toxicity,
including increases in oxidative stress via dysfunction of cellular antioxidant systems, activation
of an inflammatory response and associated proteins, and induction of programmed cell death
(Gong et al., 2015; Zager et al., 2007; Zhang et al., 2013).
We examined TNFα as a potential indicator of oxidative stress. Our study showed that
TNFα was released into the media at 72 h, while tissue showed a decline in expression at 48 and
72 h (Figure 9, Chapter 2). Because TNFα expression was unaltered at 24 h (Figure 9, Chapter 2)
it is unlikely that activation of inflammatory response is the cause of the oxidative stress
observed. The decline in TNFα in the cells is consistent with loss from cells into the media;
TNFα released into the media may contribute to greater oxidative stress.
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TFV Alters Mitochondrial Function in HK-2 Cells
The renal proximal tubular epithelial cell has a high requirement for ATP generation to
maintain normal cellular processes such as active transport. The decline in cellular ATP levels
caused by TFV would impair normal proximal tubular epithelial cell function. In our initial
study, we determined that TFV greatly diminished ATP levels following 72 h exposure but not at
24 or 48 h exposure (Figure 6, Chapter 2). Loss in cellular ATP was also seen in our subsequent
studies using Seahorse XFp; ATP production was not altered at 24 or 48 h TFV exposure, but
was diminished at 72 h (Figure 20, 21, and 22, Chapter 3). While what is causing this loss in
ATP production remains unclear, it may be due to several factors. Cytochrome c is a key
component of the electron transport chain; cytochrome c mitochondrial leakage into the cytosol
may contribute to the observed loss in ATP.
TFV appears to directly alter the electron transport chain, which may also contribute to
loss of cellular ATP. At 24 and 48 h TFV exposure, maximal OCR is lower relative to control
but basal OCR is unaffected (Figure 17, Figure 18, Chapter 3) when measured using Seahorse
XFp technology. ECAR is not affected at either time point. However at 72 h TFV exposure,
basal OCR and ECAR, and maximal OCR and ECAR are lower relative to control. Upon further
investigation in the mitochondrial stress test, 72 h TFV exposure results in lower ATP
production, but does not affect spare capacity. The results of our study suggest that TFV induces
mitochondrial changes similar to other mitochondrial toxicants.
One study using hepatocellular carcinoma cells to evaluate 27 compounds found that
seahorse technology can be helpful in mitochondrial mechanistic studies. Compounds such as
rotenone, a known complex I inhibitor, show a decrease in OCR and spare capacity, but an
increase in ECAR. ATP synthase inhibitors such as oligomycin, show a decrease in OCR with
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no effect on reserve capacity, while uncouplers such as 2,4-dinitrophenol increase OCR and
ECAR with no effect on reserve capacity (Eakins et al., 2016). These extracellular flux assays
were able to correctly predict the mechanisms of mitochondrial toxicity in 76% percent of known
test compounds used. As TFV reduces OCR but does not alter spare capacity, it is possible that
TFV inhibits ATP synthase activity. Our studies indicated that ATP synthase expression was not
diminished by TFV. It is unlikely that loss of ATP synthase from the mitochondrial membrane
contributes to the observed reduction in cellular ATP following TFV exposure.
TFV Causes Multiple Mechanisms of Cell Death
Our study shows a loss of cell viability following TFV exposure within 24-48 h via
necrosis. However, markers of apoptosis are not observed until 72 h exposure. Release of
cytochrome c to the cytosol induces apoptosis via binding to Apoptotic protease activating factor
1 (Apaf-1) to form an apoptotic complex that activates caspase 9 and eventually caspase 3 (Jiang
& Wang, 2000; Liu et al., 1996). Following 72 h exposure to TFV, there is observable release of
cytochrome c into the cytosolic subcellular fraction as well as cleavage of caspase 3 and 9.
These results are indicative that TFV causes mitochondrial damage that initiates apoptosis.
When cells undergo necrosis, organelles swell and break down, leading to disruption of
plasma membrane integrity (Challa & Chan, 2010; Moquin & Chan, 2010; Schweichel &
Merker, 1973). This loss in membrane integrity leads to the release of intracellular contents.
LDH is a stable enzyme that is expressed in every cell type; it is commonly used as a marker of
necrosis (Burd & Usategui-Gomez, 1973; Chan et al., 2013). Our study showed an increase in
LDH release from HK-2 cells into the media following 24 and 48 h exposure (Figure 13, Chapter
3), indicating that TFV induces necrosis in HK-2 cells within 24 h exposure. These findings are
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in line with clinical data of patients with TDF induced renal injury, which show marked tubular
necrosis (Herlitz et al., 2010).
Antioxidant Pretreatment Prevents TFV Cytotoxicity
Resveratrol and ascorbic acid are widely known as antioxidants and have been shown to
prevent renal toxicity of a number of chemotherapeutic agents that induce oxidative stress in
vitro and in vivo rodent models, including cisplatin and cadmium (Do Amaral et al., 2008; Fu et
al., 2017; Koyuturk et al., 2007; Maliakel et al., 2008; Valentovic et al., 2014). N-acetyl-Lcysteine (NAC) is the precursor to glutathione (GSH), an important cellular antioxidant. NAC is
most notably used to treat acetaminophen overdose by providing cysteine for glutathione
synthesis to mitigate hepatic toxicity, but has been shown to protect hepatocytes from oxidative
damage induced by cadmium and mercury in rats (Joshi et al., 2014; Wang et al., 2014).
Our study shows that a one h pretreatment with resveratrol, NAC, or ascorbic acid
protects HK-2 cell viability when exposed for 24 h to 3 or 14.5 μM TFV (Figure 6, Chapter 2).
It should be noted that high concentrations of NAC (0.5-1 mM) were required to induce a
protective effect; resveratrol may be the best choice in prevention of TFV induced cytotoxicity as
it required the lowest concentration to induce a protective effect (5 μM). It is unclear by what
mechanism antioxidants protect against TFV toxicity. Our studies did not show markers of
oxidative damage (protein carbonylation and 4-HNE adduct formation) until 72 h exposure, but
protection was observed within 24 h TFV exposure.
Conclusions
My dissertation research over the last four years has led to a general understanding of the
mechanism of TFV induced cytotoxicity. This mechanistic understanding is essential if clinical
methods of prevention are to be developed. We have determined that upon entry into the
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proximal tubule cell, TFV causes necrotic cell death within 24- 48 h. TFV enters the
mitochondria and causes oxidative stress, leading to increased protein carbonylation, a loss of
cellular ATP production, lipid peroxidation, and a loss of mitochondrial membrane integrity.
This loss of membrane integrity leads to leakage of cytochrome c and MnSOD to the cytosol,
where cytochrome c activates caspase 9 and 3, leading to apoptotic cell death within 72 h
exposure (Figure 27). Although multiple mechanisms of cell death appear to be involved,
pretreatment with NAC, ascorbic acid, or resveratrol protected against TFV cytotoxicity within
24 h. Resveratrol showed the most effective protection, and warrants further study into possible
clinical prevention of TFV induced nephrotoxicity.
Future Directions
My study was the first to investigate the mechanism of TFV induced cytotoxicity in
depth. While it has answered many questions, there are several left unanswered. It remains
unknown what causes the observed loss in cellular respiration and ATP levels; while inhibition
of ATP synthase may play a role, more work needs to be done to determine whether TFV
directly alters function of electron transport enzymes. Additionally, what triggers necrotic cell
death at lower exposure time points is unknown at this time. This alternate mechanism of
toxicity may play a role in the observed antioxidant protection at 24 h TFV exposure. Additional
research needs to be conducted to determine what mechanism triggers necrotic cell death, how
antioxidants prevent this, and if antioxidants are also effective at longer treatment periods.
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Figure 27. Summary of TFV induced cytotoxicity. TFV enters the proximal tubule cell via
OAT 1/3 transporters. TFV induces necrotic cell death by an unknown mechanism. TFV enters
the mitochondria and reduces cellular respiration and ATP levels, causes oxidative stress and
mitochondrial damage. Mitochondrial damage leads to the release of MnSOD, cytochrome c,
and TNFα. Cytochrome c release activates caspase 9 and 3, leading to apoptotic cell death.
Necrotic cell death can be prevented with antioxidant pretreatment.
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APPENDIX B: LIST OF ABBREVIATIONS
4-HNE….4-hydroxynonenal
ADP….adenosine diphosphate
AIDS….Acquired Immunodeficiency Syndrome
Apaf-1….Apoptotic protease activating factor 1
ART….antiretroviral therapy
Asc….ascorbic acid
ATCC….American Type Culture Collection
ATP….adenosine triphosphate
AUC….area under the curve
BSA….bovine serum albumin
BMD….bone mineral density
BUN….blood urea nitrogen
CI….confidence interval
COBI….cobicistat
COX-IV….cytochrome c oxidase IV
CYP….cytochrome P450
DMSO….dimethylsulfoxide
DNPH….dinitrophenylhydrazine
EC50….effective concentration in 50% of population
ECAR….extracellular acidification rate
EFV….efavirenz
EVG….elvitegravir
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FCCP….carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
FDA….Food and Drug Administration
FSGS….focal segmental glomerulosclerosis
FTC….emtricitabine
GFR….glomerular filtration rate
GSH….glutathione
HAART….highly active antiretroviral therapy
HBV….hepatitis B
HIV….human immunodeficiency virus
HIVAN….HIV-associated nephropathy
HK-2….human kidney 2
HRP….horse radish peroxidase
LDH….lactate dehydrogenase
LPV….lopinavir
MDCKII….Madin-Darby canine kidney II
MnSOD….manganese superoxide dismutase
MtCO-1….mitochondrial-encoded cytochrome c oxidase subunit
MRP1….multidrug resistance-associated protein 1
MRP2….multidrug resistance-associated protein 2
MRP3….multidrug resistance-associated protein 3
MRP4….multidrug resistance-associated protein 4
MtDNA….mitochondrial DNA
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MTT….3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NAC….N-acetyl-L-cysteine
NADPH….nicotinamide adenine dinucleotide phosphate
OAT1….organic anion transporter 1
OAT3….organic anion transporter 3
OCP….oral contraceptive pills
OCR….oxygen consumption rate
PBMCs….peripheral blood mononuclear cells
PBS….phosphate buffered saline
Pgp….P glycoprotein
PrEP….pre-exposure chemoprophylaxis
Res….resveratrol
RNS….reactive nitrogen species
ROS….reactive oxygen species
RPV….rilpivirine
RTV….ritonavir
SQV….saquinavir
TAF….tenofovir alafenamide
TBST….tris buffered saline plus Tween 20
TDF….tenofovir disoproxil fumarate
TDP….tenofovir diphosphate
TFV….tenofovir
TMB….3,3t,5,5t-tetramethylbenzidine
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TNFα….tumor necrosis factor alpha
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